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Overview
This thesis aims to explore the effects of “Skunk,” a high potency variety of cannabis 
which now accounts for 81% of the cannabis sold in the UK. A causal link between 
cannabis use and schizophrenia has been established but little is known about the impact 
of skunk or whether users experience psychotic-like or prodromal symptoms. Skunk has 
a higher percentage of tetrahydrocannabidiol (A-9-THC), the main psychoactive 
ingredient in cannabis, than traditional cannabis. Acute exposure to A-9-THC has been 
shown to cause transient psychotic symptoms in healthy individuals. However, despite 
the prevalence of its use, no study to date has explored the impact of skunk cannabis on 
recreational users. Part one of the thesis is a literature review of the evidence of how 
cannabis use might contribute to prodromal symptomatology of schizophrenia. It 
focuses on the neurobiological and cognitive effects of cannabis and how these are 
mediated by specific vulnerability factors. The review highlights the need for greater 
understanding of higher potency cannabis that dominates the UK market today.
Part two is an empirical paper that reports a study of prodromal symptoms of 
schizophrenia in daily skunk users. The study was part of a larger study investigating 
the impact of drugs being carried out at UCL. It is connected to two other DClinPsy 
theses separately investigating the effects of cocaine (Lisa Monaghan, Royal Holloway) 
and ketamine (Suzanna Duffin, UCL). To index prodromal and psychotic-like 
symptoms, 27 heavy skunk users and 20 non skunk using controls completed the 
Schizophrenia Proneness Instrument -  Adult version (SPIA), the Oxford-Liverpool 
Inventory of Feelings and Experiences (O-LIFE) the Peters Delusion Inventory (PDI)
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and the Dissociative Experiences Survey (DES). They were also administered prose 
recall, fluency and superstition tasks as these are key areas of cognitive impairment 
reported in the prodrome and psychosis. The paper reports the distinct pattern of 
prodromal symptomatology found in daily skunk users and highlights the need for 
further longitudinal studies to investigate what happens to these “prodromal” skunk 
users.
Part 3 comprises a critical appraisal of and reflections on the research as a whole.
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Parti
Literature Review
“How might cannabis use contribute to prodromal symptoms of
schizophrenia?"
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Abstract
Epidemiological studies have associated cannabis use with schizophrenia for decades. 
In the past decade meta-analyses of this research have helped to establish a causal link 
between cannabis use and the onset of psychotic symptoms as a result of both acute 
experimental studies and longitudinal studies of recreational use. Despite this, there is 
limited understanding of the mechanisms by which cannabis might contribute to the 
symptoms of schizophrenia. This review presents research on the effects of cannabis in 
relation to the symptoms of those found in the prodromal phase of schizophrenia, 
individuals at high risk of developing full psychotic episodes. The importance of 
investigating the prodrome is outlined before some of the similarities of the 
phenomenological experiences of the prodrome and those caused by cannabis are 
illustrated. The paper reviews the cognitive, neurobiological and structural evidence of 
how cannabis might contribute to the prodrome. The review includes the vulnerability 
factors that have been shown to mediate these effects. Finally, the paper highlights the 
evidence that the psychoactive potency of cannabis in the British market has grown and 
the absence of research into the effects of the recreational use of “skunk,” a high potency 
variety of cannabis which accounts for 81% of the cannabis sold in the UK today.
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1. Introduction
This review investigates the association reported between cannabis and schizophrenia 
by looking at how cannabis might contribute to prodromal symptoms of 
schizophrenia. The paper presents the importance of investigating the prodrome and 
reviews the neurobiological and cognitive changes found in individuals who have 
been identified to be in the prodromal phase of schizophrenia. It illustrates the 
common neurobiological and cognitive changes that have been reported as a result of 
both acute administration and recreational use of cannabis. It then reviews 
vulnerability factors that have been shown to mediate these changes such as 
genotypes, schizotypy, life-events and the age of first use of cannabis as well as the 
dose-response findings. Finally, the paper highlights the lack of literature on the use 
of high potency cannabis, “skunk,” that currently dominates British cannabis 
consumption, and the need for further investigation.
For the purpose of this review the databases MEDLINE and PsychlNFO 1966-2007 
were searched and the parameters used provided papers with any one of the following 
key words: cannabis, marijuana, tetrahydrocannabinol, A-9-THC , prodrome, ultra 
high risk with any of these key words: cognition, neurobiology, neuropsychology.
2. Cannabis
Cannabis is the most widely used, illegal drug in the world (World Health 
Organisation, 2007). Cannabis use dates back to the Neolithic age (Mikuriya, 1969: 
Rudgeley, 1999) and it is the third most common drug of choice in Europe after 
alcohol and tobacco (Calafat et al., 1999). According to the European Monitoring
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Centre for Drugs and Drug Addiction (EMCDDA, 2007) it is now second only to 
heroin as the primary substance of misuse in those seeking treatment of addiction.
The co-morbidity of substance abuse and schizophrenia is approximately 50% 
(Gentil, 2003). Until recently, the direction of causality between cannabis use and the 
experience of psychotic symptoms associated with schizophrenia has been under 
debate (Thomicroft, 1990). However, there has been an increase in clinical, 
experimental, prospective and epidemiological evidence indicating that cannabis use 
is a significant risk factor for the emergence of schizophrenia (van Os et al., 2002; 
Fergusson et al., 2006). Systematic reviews and meta-analyses have suggested that 
there is a causal relationship between cannabis and psychosis (Arsenault, 2004; 
Moore et al., 2007; Semple et al., 2005). The most recent meta analysis found an 
increased risk of any psychotic outcome to be approximately 40% in individuals who 
had ever used cannabis (pooled odds ratio = 1.41, 95%). This figure was elevated to 
a 50-200% increase in the risk for participants who used cannabis most heavily 
(Moore et al., 2007). There is also good evidence that cannabis intoxication may lead 
to brief psychotic episodes or recurrence of psychotic symptoms in individuals with a 
history of schizophrenia (Mathers and Ghodse, 1992; Fletcher and Honey, 2006). In 
the last two decades cannabis use has significantly increased among adolescents, and 
the age of first use has fallen considerably in many countries (Aust, 2002).
Both Boydell et al. (2006) and Moore et al. (2007) suggest that increased cannabis 
consumption may be related to the increasing prevalence of schizophrenia. Boydell 
et al. (2006) showed a steady increase in the number of patients who reported using
cannabis before their first episode of psychosis between 1965 and 1999 in south 
London. Indeed, Moore et al. (2007) estimate that 14% of those currently diagnosed 
with schizophrenia would not have been if they had not used cannabis.
The primary psychoactive constituent of the hemp plant Cannabis Sativa is the 
cannabinoid, delta-9-tetrahydrocannabinol (A-9-THC). Cannabinoids have a long 
history of consumption for recreational, religious and medical reasons. In humans, 
cannabinoids are known to produce euphoria, pain relief, enhancement of sensory 
perception, tachycardia, antinociception, difficulties in concentration and impairment 
of memory (Solowij, 1998). Taken in high doses (acutely), A-9-THC has been 
reported to produce psychotic symptoms such as visual and auditory hallucinations, 
delusional ideas and thought disorder in healthy volunteers (D’ Souza, 2004). A-9- 
THC has also been shown to exacerbate positive and negative symptoms, perceptual 
alterations and learning and memory deficits in patients with schizophrenia (D’Souza 
et al., 2005).
However, from their examination of the evidence, Arsenault et al. (2004) conclude 
that cannabis use appears to be neither a sufficient nor necessary cause for psychosis. 
They state that it is a component cause that is part of a complex constellation of 
factors leading to psychosis and just how A-9-THC in cannabis contributes to 
psychotic symptoms remains a major question.
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3. Why investigate the prodrome?
In 1997 Knapp et al. estimated the total cost of schizophrenia to the National Health 
Service (NHS) to be approximately 2.6 billion per year (5.4% of the total NHS inpatient 
costs). There is a vast amount of epidemiological evidence associating cannabis and 
schizophrenia but limited literature on how cannabis use might contribute to individuals 
developing the disorder. The construct of “the prodrome” is still much debated but it is 
agreed that there is a period of symptom development before the onset of diagnosable 
schizophrenia. In the Manheim schizophrenia study (Hafner et al, 1999), a large 
retrospective study of the early course of first episode schizophrenia, negative and 
cognitive-perceptive disturbances were found in 73% of patients on average 5 years 
before the first psychotic symptoms occurred and 6.3 years before the first 
hospitalization. Whether or not these changes turn out to be ‘prodromal’ (heralding a 
transition to psychosis) or not, they clearly present a period of ultra-high risk for 
subsequent psychopathology.
As the NHS improves its focus on preventative mental health treatment, the need for 
understanding the developmental pathways of disorders becomes greater. Research on 
the ‘prodrome’ or ultra high risk period can contribute to a preventative approach for 
mental health services in terms of both pharmacological and therapeutic intervention. 
Predicting transitions to psychosis is difficult but the more we can understand about 
common pre-psychotic experiences the better. Understanding links between the 
phenomenology and neurobiology of pre-psychotic experiences can facilitate predictions 
and the development of services to help people in the distress associated with the 
disorder. Early intervention is crucial if services hope to prevent the psychological and
social disruption that results from psychosis; delay in such intervention is associated 
with poorer outcome (Johnstone et al., 1986; Loebel et al., 1992).
It has been proposed that cannabis use leads to cognitive deficits of a similar nature to 
those seen in schizophrenia but of a lower magnitude (Solowij et al., 2007). From a 
neurobiological perspective, investigations into a drug like cannabis that causes 
dysregulation of dopaminergic neurotransmission might model the dysregulation 
reported in people with prodromal symptoms of schizophrenia. Drug models of those at 
risk of schizophrenia can be useful if a drug provokes features characteristic of the 
disorder. Drug models are especially helpful in developing new treatments and our 
understanding of the pathophysiology of psychosis.
4. Identifying the prodrome
Although identifying the schizophrenia prodrome is associated with substantial 
challenges, it is an area of study that has recently made considerable progress (White et 
al., 2006). The prodrome precedes the acute phase of a psychotic episode and extends 
from pre-morbid (“normal”) functioning to the onset of full symptoms of schizophrenia. 
Operationally, the prodrome is defined by duration of time, starting with the onset of 
decline in the baseline level of functioning and ending at the time when the criteria for a 
schizophrenia spectrum diagnosis is met (Yung, 1996). It is characterised by the 
progressive deterioration of functioning and emergence of sub-threshold psychotic 
symptoms. If recognised prospectively, the existence of a defined prodrome offers the 
opportunity for early intervention. This prodromal period can vary in time from 2-6
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years (Addington and Addington, 1998; Schultze-Lutter et al., 2007) and is associated 
with significant levels of disability.
While the clinical hallmark of schizophrenia is psychosis (Kapur, 2003), defining the 
prodrome has proved difficult. Fundamentally, the prodrome is a retrospective concept -  
only confirmed by the subsequent development of the acute, fully developed illness. 
Furthermore, many of the symptoms attributed to the prodrome are highly non-specific 
for psychosis (Phillips et al., 2000). The most common prodromal symptoms include 
magical thinking, unusual perceptual experiences, social isolation, withdrawal, impaired 
role function, blunted affect, depressed mood, sleep disturbance, reduced concentration, 
irritability, anxiety and lack of initiative or energy (Yung, 2003).
Operationally, two schools of thought predominate: the ‘ultra high risk’ (UHR) approach 
and the Basic Symptom Approach (Olsen and Rosenbaum, 2006). Putative risk criteria 
for psychosis were first defined and evaluated by Yung et al. (1996, 2003). The Ultra 
High Risk” (UHR) criteria reflect the influence of retrospective patient reports, symptom 
research and genetic risk studies. They focus on attenuated positive symptoms, brief 
intermittent psychotic states and a genetic risk for psychosis coupled with recent 
significant loss of social and instrumental capacities. Studies on UHR individuals have 
reported first-year transition rates to frank psychosis between 34% (Yung et al., 2004) 
and 65% (Miller et al., 2002) for those not participating in treatment groups of 
preventative intervention studies.
Since then, a number of different instruments measuring the prodrome have been 
produced. These include the Structured Interview for Prodromal Symptoms (SIPS) from
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the PRIME prodromal team at Yale university (McGlashan et al., 2001), the 
Comprehensive Assessment of At Risk Mental States (CAARMS) from the University 
of Melbourne (Yung et al., 2003), and The Schizophrenia Proneness Instrument (SPI) 
from the University of Cologne (Schultze-Lutter et al., 2004). In terms of validity, many 
of the studies of these instruments suffer from small sample sizes and low participation 
rates (Miller et al., 2003) and the measurement of the prodrome is still in development.
Schultze- Lutter et al’s (2004) Schizophrenia Proneness Instrument (SPI) is based on the 
basic symptom concept This is an integrative approach similar to the vulnerability- 
stress-coping model (Nuechterlein, 1992) that originates in the observation of deficits 
that were perceived by individuals with schizophrenia pre-psychotically, years before 
the first psychotic manifestation, or prior to relapses. Schultze- Lutter et al.’s basic 
symptoms are mild, often sub-clinical but self-experienced disturbances of drive and 
affect, of thought, speech, perception, proprioception and motor action as well as of 
vegetative functions. Klosterkotter et al. (2001) assessed German patients for the 
presence of “basic symptoms” using the Bonn Scale for the Assessment of Basic 
Symptoms (BSABS) and in an average follow-up period of 9.6 years, 49.4% of the 
cohort had developed schizophrenia. The prodromal symptoms that occurred in 25% of 
the patients who later developed acute schizophrenia included decreased ability to 
discriminate ideas of reference, derealisation and visual and acoustic disturbances in 
perception. Simon et al. (2006) extended the Ultra High Risk model (Yung et al., 2004) 
to determine initial prodromal states (IPS) with basic symptoms which have been shown 
to define more homogenous subgroups than UHR criteria alone.
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In their recent study examining individuals who go on to develop schizophrenia, 
Schultze-Lutter et al (2007) reported twenty seven basic symptoms that were 
significantly more frequent at the first examination in any prodromal group when 
compared with the control group. These were mainly disturbances of attention, thought, 
perception and motor action. From their study, they conclude the existence of diverse 
prodromal pathways (as opposed to a singular concept).
Yung et al., (2005) have added some of Schultze-Lutter et al’s Basic Symptoms to their 
Comprehensive Assessment of At Risk Mental States (CAARMS) for the identification 
of individuals likely to develop psychotic disorder. Table 1 shows the subscales that 
they propose identify the prodromal features of schizophrenia and the research groups 
who have identified these elements as “prodromal.”
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Table 1. Subscales proposed for the Prodrome/ Ultra High Risk for Schizophrenia
Prodrome Subscale Reported in Prodrome/ UHR
1. Disorder of Thought Content 
(Assessing obsessions, delusional mood, over­
valued ideas and delusions)
2. Perceptual Abnormalities 
(Assessing distortions, illusions and 
hallucinations)
3. Conceptual Disorganisation 
(Assessing subjectively experienced 
difficulties with forming thoughts as well as 
formal thought disorder)
4. Motor Changes
(Assessing subjectively experienced 
difficulties with movement as well as objective 
signs of catatonia)
5. Concentration and Attention
6. Disorders of Emotion and Affect 
(Assessing subjective sense of change in 
emotions and objective rating of blunting of 
affect)
Yung et al., 2005: McGlashan et al 
2001: Schultze- Lutter et al., 2004
Yung et al., 2005: McGlashan et al 
2001: Verdoux et al., 2003
Yung et al., 2005: McGlashan et al 
2001: Schultze- Lutter et al., 2004
Yung et al., 2005: McGlashan et al 
2001: Schultze- Lutter et al., 2004; 
Niendam et al., 2006
Yung et al., 2005: Schultze- Lutter 
et al., 2004; Hambrecht et al., 
McGlashan et al 2001: 2002; 
Simon et al., 2006: Hawkins et al; 
2004:Hawkins et al., 
2004:Gschwandtner et al., 2003
Yung et al., 2005: McGlashan et al 
2001: Schultze- Lutter et al., 2004
7. Subjectively Impaired Energy Yung et al., 2005: McGlashan et al
2001: Simon et al., 2006 (avolition)
8. Impaired Tolerance to Normal Stress Yung et al., 2005: McGlashan et al
 __________________________________2001: Schultze- Lutter et al., 2004
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5. Prodromal symptoms reported as a result of cannabis use
Although no single study has systematically investigated whether heavy cannabis users 
report experiencing symptoms identified in the prodrome, several researchers have 
studied the impact of the acute administration of A-9-THC and of disturbances reported 
as a result of recreational cannabis use in one or more area of psychological functioning. 
Table 2 summarises these organised according to the ‘UHR symptom’ breakdown 
described above.
Table 2. Prodromal Symptoms reported as a result of acute administration of A-9-THC 
and recreational use of Cannabis.
Ultra High Risk Symptom Reported in 
administration of 
acute A-9-THC
Reported in 
Recreational 
Cannabis users
1. Disorder of Thought Content D’ Souza et al., 2004
2. Perceptual Abnormalities D’Souza et al., 2004 Verdoux et al., 
2003;
Schiffman et al., 
2005
3. Conceptual Disorganisation D’Souza et al., 2004
4. Motor Changes Ramaekers et al., 2006 Varmaet al.,1988;
5. Concentration and Attention Fletcher et al., 1996 Popeetal., 1995;
Solowij et al., 1998 
D’Souza et al., 2004 
Wadsworth et al.,2006
Solowij etal., 1995
6. Disorders of Emotion and Affect Wadsworth et al., 
2006
Lynskey et al., 2004
7. Subjectively Impaired Energy Barkus et al., 2005
8. Impaired Tolerance to Normal 
Stress
D’Souza et al., 2004 Patton et al., 2002
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5.1 Disorder of Thought. Perceptual Abnormalities and Conceptual 
Disorganisation
There is little dispute that cannabis intoxication can lead to acute transient psychotic 
episodes in some individuals (Arsenault et al., 2004). D’Souza et al. (2004) reported 
that acute administration of A-9-THC produced transient positive and negative 
symptoms resembling those in schizophrenia. In their 3- day, double-blind, 
randomized and counterbalanced study, the behavioural, cognitive and endocrine 
effects of 0, 2.5 and 5mg of intravenous A-9-THC were characterized in 22 healthy 
individuals who had been exposed to cannabis but never diagnosed with a cannabis 
abuse disorder. Participants were screened for any vulnerability to schizophrenia. A- 
9-THC produced symptoms including suspiciousness, unusual thoughts, paranoia, 
thought disorder, thought blocking, blunted affect, reduced spontaneity, reduced 
interaction with the interviewer and problems with memory and attention. In a 
separate study, using an experience sampling method, Verdoux et al., (2003) found 
that in daily life, recreational cannabis use is an independent predictor of unusual 
perceptual experiences.
5.2 Motor Changes
The motor impact of cannabis has been investigated with particular focus on driving 
(Robb, 1993). There is consistent evidence that consumption of cannabis impairs motor 
control. Most of the studies of motor control impairment have used tasks such as 
maintaining a stylus within a fixed target area or remaining balanced while stationary on 
a platform supported by a fulcrum. Even for low doses (10 pg/kg), hand and body
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instability increases. The effect is dose related in that higher levels of consumption 
produce proportionally greater instability. Robb, 1993 suggests that the consumption of 
cannabis interferes with processing of proprioceptive feedback involved in motor 
control.
Varma et al. (1988) studied 26 Indian cannabis users and found they reacted 
significantly more slowly in perceptual-motor tasks than controls. Ramaekers et al. 
(2006) also reported deficits in control of motor impulsivity as a result of cannabis 
intoxication. Those administered higher doses showed greater difficulty inhibiting an 
activated or pre-cued response leading to errors of commission.
53 Concentration and Attention
A host of studies have identified difficulties in concentration and attention as a result of 
both acute A-9-THC and recreational cannabis use. D’Souza et al. (2004) reported 
transient impairments in attention in their research on acutely administering A-9-THC 
and Solowij et al. (1995) found that the ability to focus attention and filter out irrelevant 
information was impaired in cannabis users. Barnett et al. (1985) found a significant 
linear correlation between tracking errors under divided attention and THC plasma 
levels over 25 ng/ml among cannabis users assessed approximately 2 hours after 
smoking. Pope et al. (1995) tested the cognitive functioning of 64 heavy cannabis users, 
whom had smoked cannabis for at least 27 out of the previous 30 days. Heavy users 
showed significant deficits in sustaining and shifting attention.
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5.4 Changes in Emotion and Affect
The negative changes in mood that are reported in the prodrome can also be found in 
investigations of the impact of cannabis use (Wadsworth et al., 2006). Research on the 
affective states of cannabis users has suggested that they are more likely than non-users 
to report feeling depressed (Bovasso, 2001). Beautrais et al. (1999) report that 
individuals with cannabis dependence (as diagnosed in DSM-IV) are at greater risk of 
suicide attempts. In their examination of the evidence of depression in cannabis users, 
Degenhardt et al. (2003) conclude that heavy cannabis use and depression are associated 
and evidence from longitudinal studies suggests that heavy cannabis use may increase 
depressive symptoms among some users. However, Degenhardt et al. (2003) state that it 
is still too early to rule out the hypothesis that the association is due to common social, 
family and contextual factors that increase risks of both heavy cannabis use and 
depression.
On the other hand, in a twin study, Lynskey et al. (2004) found that the twin who was 
cannabis dependent was more 2.5 to 2.9 times more likely to have had a major 
depressive disorder, suicidal ideation and attempted suicide than their non-cannabis 
using twin. Interestingly, this was only the case for dizygotic twins and not for 
monozygotic twins. This suggests that one of the factors contributing to the comorbidity 
of cannabis dependence and major depressive disorder may be a genetic element. Both 
the Degenhardt (2003) review and the Lynskey (2004) study point to vulnerability 
factors which will be discussed further in this review.
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5.5 Decrease in Energy
A decrease in mental energy has been reported as an effect of cannabis use. The 
“amotivational syndrome” amongst cannabis users described by McGlothin and West 
(1968) includes apathy, loss of effectiveness, a diminished ability to concentrate, to 
follow routines, and successfully master new material. This loss of motivation as a 
negative effect of cannabis was reported by Barkus et al., (2005). However this 
“syndrome” of apathy and lethargy has been poorly documented in uncontrolled studies 
in the past. It is difficult to distinguish the effects of heavy cannabis use from those of 
poverty and low socioeconomic status, pre-existing personality and other psychiatric 
disorders. Musty and Kaback (1995) attributed the amotivational symptoms they 
reported in a sample of heavy cannabis users to coexisting depressive symptoms and 
other studies have not found an association between cannabis use and lack of motivation 
(Foltin et al., 1990; Barnwell et al., 2006). However, in a recent online study of 2500 
adult daily cannabis users, dependent users did report lower levels of motivation than 
non-dependent users (Looby and Earleywine, 2007).
5.6 Changes in Tolerance to Stress
D’Souza et al. (2004) found that A-9-THC increased levels of the stress hormone 
cortisol and it is not surprising that heavy cannabis users show a decreased tolerance 
to stress. In a seven wave cohort study involving 1601 students over six years (Patton 
et al., 2002), daily cannabis use in young women was associated with an over five­
fold increase in the odds of reporting a state of anxiety (after adjustment for other 
substance misuse).
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Section 5 has outlined the studies that have reported different high risk symptoms in 
recreational cannabis users and as a result of the acute administration of A-9-THC. 
Clearly, associations do not allow us to assume that these high risk symptoms are caused 
by A-9-THC and there may well be other factors that cause both or incidental issues 
around testing such as motivation and the acute effects of cannabis. Section 7 addresses 
vulnerability factors that have been shown to mediate these associations.
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Evidence of the link between cannabis and the prodrome
The following section addresses the cognitive, neurobiological and structural evidence 
that supports the link between cannabis use and symptoms identified in the prodrome.
6.1 Cognitive evidence for the link between cannabis and the prodrome
Over the last 50 years empirical research has demonstrated that cognitive deficits are a 
core feature of schizophrenia (Heinrichs and Zakznis, 1998). Cognitive impairment in 
prodromal patients who have gone on to develop schizophrenia has been widely reported 
using evidence from baseline assessments on neuropsychological test performance 
(Hambrecht et al., 2002: Simon et al., 2006). The main deficits have been found in 
memory, attention, language and executive function. These are deficits that have also 
been sometimes reported in cannabis users, although the research is not consistent. 
Solowij et al. (2007) argue that the similarities of these deficits provide a link in the 
experience of those in the prodrome and heavy cannabis users and illustrates how 
cannabis users can also be “at risk.”
From a phenomenological perspective, it is understandable how individuals who are 
finding it difficult to remember, sustain attention, communicate, monitor their behaviour 
and thoughts and plan and organise themselves might find it harder to process their 
experiences. It is not difficult to imagine how these deficits may lead to confusion, 
misattribution and distorted thinking. The following section provides a summary of the 
cognitive deficits reported in prodromal individuals (6.1.1) before describing the deficits 
reported as a result of acute A-9-THC and among recreational cannabis users (6.1.2). 
The section concludes with the question of the duration of the cognitive deficits of
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cannabis use (6.1.3). Table 3. presents a summary of studies (produced from the research 
criteria outlined in section 1) reporting cognitive deficts (i) in the prodrome (ii) as a 
result of acute and (iii) among recreational cannabis users.
Table 3. Summary of studies reporting cognitive deficits in individuals at ultra high 
risk or in the schizophrenia “prodrome.” following acute cannabis administration and 
in recreational cannabis users.
Cognitive 
function assessed
Prodrome/ UHR Acute A-9- 
THC
Recreational 
Cannabis users
Verbal memory Curran et al., 2002; 
Hawkins et al., 2004; 
Lenez, 2006; 
Niendam, 2006; 
Pukrop et al 2006
Fletcher et al 
1996; Messinis 
et al., 2007
Heishman et al., 
1997; Varmer et 
al, 1988
Working
memory
Wood et al., 2003; 
Simon et al., 2006; 
Niendam et al., 2007; 
Gshwandtner et al., 
2003
D’Souza et al., 
2004; Llan et 
al., 2004
Schwartz et al., 
1989; Pope et 
al., 1995: 2001
Episodic
memory
Curran et al., 
2002; Llan et 
al., 2004
Visual
Reproduction
Wood et al, 2005; 
Pamas et al., 2001; 
Niendam, 2007
Verbal fluency Simon et al., 2006; 
Pukrop et al., 2007
Curran et al., 
2002
Messinis et al., 
2006
Verbal
expression
Schultze-Lutter et al., 
2004
Block and 
Ghoneim, 1993
Table continued overleaf...
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Cognitive 
function assessed
Prodrome/ UHR Acute A-9- 
THC
Recreational 
Cannabis users
Attention Hambrecht et al., 
2002; Hawkins et al., 
2004; Gschwandtner 
et al 2003
Barnett et al., 
1995; Fletcher 
et al., 1996; 
Solowij et al., 
1998; D’Souza 
et al., 2004; 
Wadsworth et 
al 2006; 
O'Leary et al., 
2002; Pope et 
al., 1995
Pope et al., 
1995: Pope and 
Yurgelun-Todd, 
1996
Executive
Function
Gschwandtner et al 
2003; Hawkins et al., 
2004; Simon et al 
2006; Niendam et al., 
2007
O’Leary et al., 
2002: Pope et 
al., 1995
Bolla et al., 2002: 
Ramaekers et al., 
2006
Processing
speeed
Niendam et al., 2006; 
Niendam et al, 2007; 
Pukrop et al., 2007;
Fried, Watkinson 
and Gray, 2005: 
Ghaffar & 
Feinstein, 2008
Psychomotor 
speed/ reaction 
times
Niendam et al., 2006; 
Gschwandtner et al., 
2003
Chait and 
Pierri, 1992; 
Curran et al., 
2002;
Ramaekers et 
al., 2006
Varma et al., 
1988
6.1.1 Cognitive deficits found in prodromal individuals
Memory - Three longitudinal studies provide evidence for memory deficits from baseline 
assessments comparing patients with UHR who went on to develop psychosis with UHR 
patients who did not within 12 months: Wood et al. (2005) observed that verbal memory
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and visual reproduction impairments were specific to UHR patients who developed 
psychosis; Lenez et al. (2006) found significantly lower verbal memory scores in UHR 
patients who later developed psychosis and Whyte et al. (2006) identified greater verbal 
learning impairment in high-risk subjects who later became psychotic. Memory deficits 
were also identified by Niendam et al. (2006) in UHR individuals using the SIPS and 
Gschwandster et al. (2003) using the IPS. Poorer verbal learning and memory 
performance was also significantly associated with poorer global functioning.
Processing Speed - Niendam et al. (2006) report that deficits in cognition have been 
shown to occur years before the development of overt psychotic symptoms. They 
identified 45 individuals as ultra-high risk (UHR) for psychosis using the Structured 
Interview for Prodromal Syndrome (SIPS, McGlashan et al. 2001). They reported that, 
despite the absence of fully psychotic symptoms, participants showed significant deficits 
in speed of processing information. This finding has been replicated by Pukrop et al. 
(2007).
Attention -  Hambrecht et al. (2002) at the Cologne Early Recognition Centre have found 
neuropsychological evidence for the prodromal symptom of reported difficulties of 
attention. They used the Continuous Performance Test (Comblatt et al., 1999) with 
individuals with a diagnosis of schizophrenia, individuals with identified prodromal 
symptoms of schizophrenia and controls. Their results suggest that the deficit in 
attention is progressive throughout the prodromal period. Individuals with prodromal 
symptoms scored significantly lower than controls but those with diagnoses of 
schizophrenia scored the lowest. However, in an outpatient clinic for early psychosis in 
Switzerland, no difficulties of sustained attention were reported in some of the
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individuals at high risk and this varied according to inclusion criteria (Simon et al., 
(2006).
Executive Junction - This is another domain that has been reported to be impaired in 
individuals at high risk (Simon et al., 2006: Pukrop et al., 2007). Niendam et al (2007) 
studied the everyday behavioural manifestations of executive dysfunction in individuals 
at UHR for psychosis. Their results indicated a high proportion (58%) of UHR show 
clinically significant behavioural signs of executive dysfunction according to parent 
report on the BRIEF (Behaviour Rating Inventory of Executive Function) (Gioia et al., 
2000a). Difficulties with executive function were also found using objective measures 
in individuals identified to be in an “Initial Prodromal State” (IPS) (Hawkins et al., 
2004; Simon et al 2006 and Gshwandtner et al., 2003 in Germany).
Language -  Language deficits have also been reported in individuals at high risk (as 
defined by the UHR criteria). The findings of Simon et al., (2006) support the 
previously reported memory and executive function impairments as well as language 
impairments tested by letter and category fluency and verbal IQ. This has also been 
supported by Pukrop et al. (2007) whose findings were that individuals at greater risk 
showed greater impairment suggesting a progression of cognitive deficits in the 
prodrome before frank psychosis.
Motor Speed - Individuals in IPS and UHR for psychosis have been reported to have 
poorer reaction times than controls (Gshwandtner et al., 2003: Niendam et al., 2006)
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Although significant cognitive differences between UHR/ IPS groups and controls have 
been reported, it is important to note that these were not unilateral differences and results 
are not consistent. Table 3 does not include studies that have not found some of the 
cognitive deficits identified by others. For example, Pamas et al. (2001) and Pukrop et 
al. (2007) found verbal memory impairments but not the spatial memory impairments 
that have been reported by others (Brewer et al, 2005: Niendam, 2007). Studying people 
who are “prodromal” or “at risk” is not easy. The significant group differences could be 
due to a number of alternative variables. Fundamentally, it is difficult to bring the 
evidence of these constructs together when research groups are using different criteria 
for the prodrome with different samples, continuums and transition rates. Furthermore, 
a significant proportion of those considered to be at risk will prove to be false-positives 
and another subset may progress with marked cognitive impairment in time.
6.12 Cognitive deficits reported following acute A-9-THC administration and in 
recreational cannabis users.
Memory - Acute neuropsychological effects (within 12-24 h) of both acutely 
administered A-9-THC and recreational cannabis use include deficits in attention, 
executive functioning, and short-term memory (O’Leary et al., 2002; Pope et al., 1995). 
One of the most consistently reported behavioural effects of A-9-THC is a disruption in 
the free recall of newly learned information. Recall of items learned before cannabis use 
is generally not affected, suggesting that A-9-THC impairs learning and the acquisition 
of information but not its retrieval from memory (Curran et al., 2002; D’Souza et al, 
2004). Curran et al., (2002) investigated the cognitive effects of acute oral A-9-THC in
infrequent cannabis users and reported that oral A-9-THC impaired episodic memory 
and learning in a dose-dependent manner whilst leaving intact performance on tasks 
tapping perceptual priming and working memory. Llan et al. (2004) found that both 
episodic and working memory were impaired after subjects smoked 3.5% A-9-THC. 
Wadsworth et al. (2006) reported that heavy recreational cannabis use was associated 
with working memory problems and poorer episodic memory and Solowij et al. (2002) 
found that long-term cannabis users show impairments in memory and attention that 
endured beyond the period of intoxication and worsened with increasing years of regular 
cannabis use.
Attention -  As detailed earlier (5.3) impairment in attention has been observed for 
several days following cannabis use (Pope et al., 1995). Attention deficits have also 
been observed in acutely administered A-9-THC (Barnett et al., 1995; Wadsworth et al 
2006).
Processing speed -  Processing speed has been reported to be slower in heavy cannabis 
users (Kelleher et al., 2004: Fried et al., 2005). Although with a small sample size, in a 
recent study, Ghaffar and Feinstein (2008) found that Multiple Sclerosis sufferers who 
smoked cannabis processed information significantly slower than their non-smoking 
controls.
Language - Block and Ghoneim (1993) matched heavy cannabis users and nonusers 
on the basis of their intellectual functioning before the onset of drug use and found
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that subjects who used cannabis 7 or more times weekly for at least 2 years showed 
deficits in verbal expression as well as selective impairments in memory.
Executive Function -  Bolla et al. (2002) reported significant deficits in executive 
function in chronic users of cannabis. Furthermore, in their study administering 0, 250, 
and 500 ^g/kg A-9-THC to participants, Ramaekers et al. (2006) found that these 
impairments in executive function were dose-related. They also found dose related 
impairments in motor control.
Perceptuo-Motor Function - Varma et al. (1988) tested a range of memory functions in 
26 long term heavy cannabis users following 12 weeks of abstinence. Using a locally 
developed and validated test battery which assessed memory in 10 different domains, 
they found significantly poor performance on a pencil-tapping test of perceptuo-motor 
function in cannabis users as well as impairments in short-term memory.
Psychomotor speed -  Reaction times have been showed to be delayed as a result of the 
acute administration of A-9-THC (Chait and Pierri, 1992: Curran et al., 2002 Ramaekers 
et al., 2006) as well as in heavy recreational users (Varma et al., 1988: Wadsworth et al., 
2006).
Again, it is easy to consider the phenomenological difficulties that might be 
experienced as a result of difficulties with memory, attention, language, executive 
function and processing information. The cognitive findings show how cannabis use
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can put individuals at risk of experiencing similar cognitive difficulties reported in 
the prodrome.
6.13 Duration of Cognitive Deficits of Cannabis Use
It is important to note that the duration of the deficits following cannabis use has been 
questioned in terms of its permanent impact on cognitive functions. The elimination 
half-life of A-9-THC has been reported to vary from 18 hours to 4.3 days (Hunt and 
Jones, 1980; Kelly, 1992) and D’Souza et al (2004, 2005) showed acute impairments 
were transient. However, in naturalistic studies of recreational use, the evidence is 
conflicting. Neuropsychological deficits found in heavy cannabis users have been 
shown to lessen a few days after cannabis use is stopped (Curran et al, 2002). Eldreth et 
al. (2004) used a modified version of the Stroop task to determine whether 25-day 
abstinent heavy cannabis users have persistent deficits in executive cognitive 
functioning. However, they showed no deficits in performance on the modified version 
of the Stroop task when compared to a non-using comparison group. On the other hand, 
Bolla et al., (2002) found persistent deficits in decision making, memory, executive 
functioning, psychomotor speed, and manual dexterity among heavy cannabis users who 
had been abstinent for 25 days.
Pope et al (2001) found that with abstinence of 28 days, long-term cannabis users 
showed no significant differences compared to non-using control groups. Lyons et al 
(2004) carried out a twin study with 54 monozygotic male twin pairs, discordant for 
regular cannabis use in which neither twin used any other illicit drug regularly. A 
minimum of 1 year had passed since the cannabis-using twins had last used the drug,
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and a mean of almost 20 years had passed since the last time cannabis had been used 
regularly. Twins were administered a comprehensive neuropsychological test battery to 
assess general intelligence, executive functioning, attention, memory and motor skills. 
They found that of these, cannabis-using twins only significantly differed from their 
non-using co-twins on the performance of the block design subtest of the Wechsler 
Adult Intelligence Scale. Executive functioning, attention, memory and motor skills 
were not significantly different, indicating an absence of marked long-term residual 
effects of cannabis use on cognitive abilities. However, it is unlikely that the twins in 
this study recruited from the Vietnam Era Twin Registry for the study were smoking the 
same kind of cannabis that dominates the UK market today.
62 Neurobiological evidence for the link between cannabis and the prodrome
Although there has been a great deal of research focusing on the neurobiology of 
schizophrenia, there is relatively little on the prodrome due to the difficulty of 
identifying people at high risk who do go on to develop schizophrenia. However, we 
can learn from the neurobiological changes identified in those suffering from the 
disorder. The following section reports evidence for a neurobiological link between 
cannabis and psychosis. This derives from dysregulations in both dopaminergic (6.2.1) 
and endocannabinoid (endogenous cannabinoid) (6.2.2) systems in individuals suffering 
with schizophrenia and the effects of A-9-THC on those same systems. It also discusses 
recent findings of the impact of another cannabinoid found in cannabis: cannabidiol 
(6.2.3).
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6.2.1 The Dopamine Hypothesis of Psychosis and A-9-THC Induced Dopamine
Dvsregulation
The Dopamine Hypothesis
For nearly three decades the dominant hypothesis about the pathophysiology of 
schizophrenia has been based on dysregulation of dopaminergic neurotransmission 
(Snyder, 1976; Carlsson, 1998). Laruelle and Abi-Dargham (1999) suggest that 
“Dopamine is the wind of the psychotic fire.” Although there is evidence that other 
neurotransmitter systems also contribute to the psychopathology of schizophrenia 
(Holcombe et al., 2004), the first-line treatment of positive symptoms is invariably with 
antipsychotics that block dopamine D2 receptors. Neuroimaging studies have shown 
heightened dopaminergic transmission in patients with schizophrenia; in the acute phase, 
psychotic patients show a higher synthesis of dopamine, heightened dopamine release in 
response to an impulse and a heightened level of synaptic dopamine (Kapur, 2003).
Kapur's (2003) framework for linking the psychological and biological in psychosis 
posits that a central role of dopamine is to mediate the “salience” of environmental 
events and internal representations. Kapur proposes that a dysregulated, 
hyperdopaminergic state leads to an aberrant assignment of salience to elements of 
one’s experience. Delusions are a cognitive effort by the patient to make sense of 
aberrantly salient experiences while hallucinations reflect a direct experience of the 
aberrant salience of internal representations. Antipsychotics dampen the salience of 
abnormal experience and thus often help reduce positive symptoms. If the 
antipsychotic treatment is stopped then dopaminergic dysregulation may occur
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leading to a relapse. Thus the altered perceptions identified in prodromal individuals, 
or individuals at high risk; captivation of attention by details of the visual field and 
unstable ideas of reference are thought to also be a result of dopamine dysregulation. 
Given early, atypical antipsychotics such as respiridone or olanzapine have been 
shown to ameliorate progression in individuals at risk of developing a psychotic 
episode (for review see Thomas and Woods, 2006).
A-9-THC Dopamine Dysregulation
Research on the neurobiological impact of A-9-THC on the brain has ranged from 
animal studies to acute exposure in humans. The A-9-THC in cannabis increases the 
activity of dopaminergic neurons in the ventral tegmental area-mesolimbic pathway 
and facilitates the release of dopamine in the brain. In-vivo SPECT studies show 
increased synaptic dopaminergic activity in response to cannabis consumption 
(Voruganti, et al., 2001). Lupica and Riegal (2005) have shown that cannabis 
significantly increases neuronal firing and burst firing and that A-9-THC increases the 
release of dopamine at synaptic terminal fields in the striatum and prefrontal cortex. 
Kapur’s ‘motivational salience hypothesis’ of schizophrenia also explains why, under 
the influence of cannabis, a hyperdopaminergic state may lead to the experience of 
positive symptoms also experienced in schizophrenia. Since dopaminergic circuits 
are known to play a pivotal role in mediating the reinforcing effects of most drugs of 
abuse, the enhanced dopaminergic drive elicited by cannabinoids is believed to 
underlie the reinforcing effects of cannabis (Ameri, 1999).
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6.2.2 Endogenous Cannabinoid Dysregulation in Psychosis and A-9-THC induced
Cannabinoid Dysregulation
Endogenous Cannabinoid Dysregulation in Psychosis
In the last few decades, a major cannabinoid receptor “CB1” and the endogenous 
cannabinoid ligand, “anandamide,” have been discovered (Devane et al., 1988; 1992). It 
has been hypothesised that a dysfunction in endocannabinoid signaling may be 
associated with schizophrenia. Giuffrida et al. (2004) have shown that cerebrospinal 
fluid (CSF) from individuals suffering from schizophrenia contains significantly higher 
levels of anandamide than CSF from healthy volunteers. They hypothesised that 
endocannabinoids such as anandamide may enhance dopaminergic neurotransmission by 
increasing dopamine turnover. They also found that CSF anandamide levels in 
antipsychotic-naive people suffering from first-episode paranoid schizophrenia are 
eight-fold higher than in healthy controls. However, interpretation of these results is 
obscured by the small number of subjects involved and the lack of systematic 
comparison with other mental disorders in which endocannabinoid signaling also might 
be dysregulated. On the other hand, anandamide has been shown to impair working 
memory in rats (Mallet, 1996) and, of all cognitive impairments reported in 
schizophrenia, the most marked are in the memory domain (Saykin et al., 1991).
Giuffrida et al., (2004) also investigated the effects of antipsychotics on CSF 
anandamide levels. They found that the alteration was absent in those that had been 
treated with antipsychotics which antagonize D2 receptors. When they compared 
Anandamide levels in those with schizophrenia who were not medicated, they found that
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Anandamide was negatively correlated with psychotic symptoms suggesting that the 
elevation of anandamide may reflect a compensatory adaptation to the disease state.
The brain’s own cannabinoids are a family of bioactive lipids that activate CB1 
cannabinoid receptors in synapses in the brain and exert intense emotional and cognitive 
effects. CB1 receptor activation has been shown to stimulate dopamine transmission 
(Pistis et al., 2001). CB1 receptors are particularly dense in the hippocampus, 
cerebellum and basal ganglia and relatively dense in the cerebral cortex, amygdala and 
some brain stem nuclei (Chevaleyre et al., 2006). These are areas of the brain that are 
involved in the control of motor functions, cognition and motivation (Giuffrida et al., 
2004). Cannabinoids also inhibit noradrenaline release at the sympathetic nerve 
terminals and centrally in the hippocampus, cortex and cerebellum. Noradrenaline is 
involved in the control of alertness and wakefulness.
Endocannabinoids allow cells to fine-tune their input and act as important synaptic 
modulators. A proposed function of CB1 receptors on synaptic terminals is that of a 
safety mechanism to prevent local network excitability progressing to excitotoxicity and 
seizures Same et al. (2005). Cannabinoids acutely reduce glutamate release and block 
hippocampal long-term potentiation (LTP), a potential substrate for learning and 
memory (Hoffman et al., 2007). LTP is a process by which the responsiveness of a 
neuron to a particular input becomes sensitized with repeated stimulation and is most 
prevalent in the hippocampus, an area of the brain important in memory (Ameri, 1999). 
Furthermore, Kim and Thayer (2001) report that cannabinoids inhibit the formation of 
new synapses between hippocampal neurons in culture. Functional imaging studies also
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reveal that people with diagnoses of schizophrenia show reduced activation of the 
hippocampus in cognitive tasks like spatial navigation that are hippocampus dependent 
(Weinberger, 1997).
A-9-THC Cannabinoid Dysregulation
The main psychological effects of A-9-THC stem from activation of the CB1 receptor in 
the brain. When individuals take cannabis the synaptic modulation by the brain’s 
endocannabinoids is disrupted, A-9-THC activates CB1 receptors and the cells are 
flooded. The effects of CB1 activation on hippocampal LTP may explain the amnestic 
effects of A-9-THC. Curran et al. (2002) describe how memory impairment is a 
predictable effect of A-9-THC given the uneven distribution of cannabinoid receptors in 
the brain with the highest densities in the hippocampus, basal ganglia and cerebellum. 
Animal studies suggest A-9-THC induced cell death with shrinkage of neurons and DNA 
fragmentation in the hippocampus (Ameri, 1999). As working memory and episodic 
memory rely on brain regions dense in CB 1 receptors, it is unsurprising that they tend to 
be disrupted in acute cannabis intoxication. A-9-THC also increases cortisol levels via 
activation of the CB1 receptor. High levels of this stress hormone have been associated 
with schizophreniform symptomatology and memory deficits (Walder et al., 2000).
The chronic effects of cannabis suggest an adaptive process. It has been shown 
postmortem that chronic cannabis abusers have a downregulation of cannabinoid 
receptors. This was illustrated by a significantly lower density of cannabinoid receptor 
positive neurons than in control brains in regions of the putamen, caudate, nucleus 
accumbens and hippocampus (Ledent, 1999). Leweke et al. (2007) investigated the
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effects of cannabis on the brain’s anandamide levels. They found that low-frequency 
cannabis users with schizophrenia exhibited more than 10-fold higher CSF anandamide 
levels than did high-frequency users with schizophrenia, healthy low-frequency or high- 
frequency users. CSF anandamide levels and disease symptoms were negatively 
correlated in both user groups. Leweke et al. (2007) suggest that the results indicate that 
frequent cannabis exposure may down-regulate anandamide signalling in the central 
nervous system of patients with schizophrenia, but not of healthy individuals. Their 
findings suggest that alterations in endocannabinoid signaling might be an important 
component of the mechanism through which cannabis impacts upon mental health. 
Their findings also provide a further link between endocannabinoid dysregulation in 
schizophrenia and that resulting from cannabis use.
6 2 J  Cannabidiol
Although A-9-THC is the main psychoactive ingredient in cannabis it is important to 
emphasize that cannabis comprises over 60 cannabinoids that are unique to the plant as 
well as 400 different chemicals. Different strains of cannabis have varied compositions 
of these chemicals. Cannabidiol (CBD) is another cannabinoid in cannabis that has been 
identified as having neuroprotective factors (luvone et al., 2004) as well as anxiolytic 
effects (Leweke, 2007). It is a major constituent of the plant.
It has been proposed that CBD mediates the effects of A-9-THC and there has been 
evidence that CBD may block the conversion of A-9-THC to the more psychoactive 11 - 
hydroxi-A-9-THC (Borheim et al. 1995). However, the CBD content of cannabis varies
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greatly and some samples of cannabis have been reported to be devoid of CBD. Morgan 
and Curran (2008) analysed hair samples of 140 young participants and took measures 
of psychosis proneness and delusional thinking. They categorized participants by 
whether their hair samples revealed detectable levels of only A-9-THC, both A-9- THC 
+ CBD or no cannabis. Their results showed higher levels of unusual experiences (an 
analogue of hallucinations and delusions) in individuals who had evidence of only A-9- 
THC in their hair compared to those with either both A-9-THC and CBD or no 
cannabinoids. There were also greater levels of delusions in the A-9-THC only group 
compared to individuals who showed no evidence of cannabis in their hair, with a 
similar trend in the A-9-THC and CBD group. This suggests that different strains of 
cannabis may manifest differing levels of psychological symptoms.
Indeed, Cannabidiol may serve as an antipsychotic medication that is not primarily 
based upon a dopaminergic but upon endocannabinoid mechanisms. In recent trials, 
CBD has been used as an antipsychotic for treatment resistant schizophrenia (Zuardi 
2006; Leweke et al., 2007). Leweke and colleagues (2007) investigated the effects of 
CBD on 42 patients with acute schizophrenia. Some were given CBD, while others 
received a standard anti-psychotic drug; amisulpride. Both groups had fewer psychotic 
symptoms, but the CBD group also experienced fewer side-effects. Common side- 
effects of amisulpride include weight gain, sexual dysfunction and liver problems and it 
is encouraging that CBD did not produce these effects.
CBD is currently under intense investigation. Varval et al (2006) investigated whether 
CBD modulates the pharmacological effects of intravenously administered A-9-THC or
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inhaled cannabis smoke on hypoactivity, antinociception (inhibition of the nociceptive 
processing in the nervous system), catalepsy, and hypothermia in mice, the well 
characterized models of cannabinoid activity. They found that intravenously 
administered CBD possessed very little activity on its own and, at a dose equal to a 
maximally effective dose of A-9-THC (3 mg/kg), failed to alter A-9-THC’s effects on 
any measure. They concluded that as the amount of CBD found in most cannabis strains 
in America is considerably less than that of A-9-THC, CBD is likely to exert little, if 
any, modulatory effects in normal cannabis.
The investigations of CBD indicate that there are further interactions of cannabinoids on 
the brain that we have yet to understand or quantify. Although the dysregulation of 
cannabinoid and dopamine systems have been implicated in both the onset of psychosis 
and cannabis use, the neurobiological evidence is far from complete. Furthermore, the 
differing compositions of cannabis that is sold in the UK (specifically A-9-THC 
potency) make it hard to generalize the effects found in small samples.
63  Structural evidence for the link between cannabis and the prodrome
Although structural changes in the brain have been reported in the prodrome and in 
chronic cannabis users, the evidence remains associative rather than causal and is far 
from conclusive. Two MRI studies of High-Risk/Prodromal individuals (Lawrie et al., 
2002: Job et al., 2003) have shown structural brain gray matter changes, particularly 
localized in the frontal and temporal lobes (anterior cingulate, temporal cortex, 
parahippocampal gyrus, frontal lobe) that are abnormal before the onset of psychotic 
symptoms. It may be that some of these anomalies may be progressive over time. The
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anterior cingulate gyrus is responsible for a number of functions including but not 
limited to cross-modal sensory processing, voice and face expression identification, 
monitoring of conflict and error, and reward-based decision making (Pillay et al., 2004). 
In addition, numerous studies have shown that the anterior cingulate is involved in 
motor function (e.g. Backus et al., 2001).
Several studies, using different techniques (PET, SPECT, fMRI), have shown subnormal 
cerebral blood flow in heavy cannabis users. Lundqvist et al. (2001) measured brain 
blood flow levels after cessation of cannabis use (mean 1.6 days). The findings showed 
significantly lower mean hemispheric blood flow values and significantly lower frontal 
values in the cannabis subjects, compared to normal controls. In their recent review of 
the evidence of the structural impact of cannabis on the brain, DeLisi et al. (2008) 
conclude that to date, brain imaging, animal and neurocognitive studies have been 
inconsistent and do not clearly show any lasting adverse effects of cannabis on the 
structure of the brain. Apart from one or two small scale studies, none of these 
abnormalities has been carefully examined in pure cannabis, as opposed to polydrug, 
users. However, Pillay et al. (2004) found decreased cingulate activation in response to 
finger sequencing among heavy cannabis users, Volkow et al. (1996) report lower 
baseline cerebellar volume in chronic cannabis smokers and Szeszko et al. (2007) 
reported that cannabis use was associated with less anterior cingulate grey matter in first 
episode schizophrenia patients.
The anterior cingulate is an area that has been focused on in both the prodrome and 
cannabis research. In Eldreth et al’s (2004) study of the effects of cannabis on executive
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function, they used PET scans to illustrate that even after 25 days’ abstinence, heavy 
users showed hypoactivity in the anterior cingulate cortex and the prefrontal cortex and 
hyperactivity in the hippocampus bilaterally when compared to the comparison group. 
These results suggest that cannabis users display persistent metabolic alterations in brain 
regions responsible for executive function. However, interpretation is difficult given 
that these differences may pre-date cannabis use.
The dorsolateral prefrontal cortex (DLPFC) is another area that may be effected by 
heavy cannabis use. Yurgelun-Todd et al. (1999) assessed chronic cannabis smokers 
twice with functional magnetic resonance imaging (fMRI), after 24 h and 28 days of 
abstinence. On a visual working memory task, control subjects showed significant 
activation in the DLPFC but smokers who completed 24 h of cannabis abstinence 
showed diminished activation in this region. The effect remained after 28 days of 
washout, although some increase in the DLPFC activation was noted relative to the 24-h 
time point. In contrast, smokers produced increased activation in the cingulate during 
both washout conditions, whereas controls did not. Their results suggest that even after 
an extended washout period, specific differential patterns of cortical activation exist in 
subjects with a history of heavy cannabis use. Causal links between cannabis use and 
brain activation are however, difficult to make in the absence of prospective research.
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7. Vulnerability
The vulnerability presented by the prodrome is not as simple as neurobiological and 
neurocognitive abnormalities (were even these simple) and it would be naive to ignore 
other vulnerability factors that have been shown to mediate the effects of A-9-THC. 
Favrat et al. (2005) have shown that individuals even vary in the sensitivity to the acute 
administration of A-9-THC where some participants developed full-blown paranoia at 
doses that barely affected others. The following section reviews the literature on the 
effects of genes, schizotypy, the impact of life events, age of first use, length of use and 
the dose of use on the effects of cannabis. In some of these areas the research findings 
have been inconsistent thus highlighting the need for further investigation.
7.1 Genotypes
Using a subgroup of the Dunedin cohort, Caspi et al. (2005) have presented evidence for 
a genetic influence over the vulnerability of individuals to the effects of cannabis. The 
catechol-O-methyltransferase (COMT) gene plays an essential role in the breakdown of 
dopamine in the prefrontal cortex. Caspi et al. (2005) suggested that COMT variability 
moderates the risk of adolescent cannabis use with at least a five-fold increased risk of 
developing a schizophreniform disorder if they had a particular type of VAL/VAL 
allelle and used cannabis. However, this was only observed in a small subgroup of 
people within the Dunedin study and evidence for the interaction in an experimental 
setting was also observed in only a small subgroup of participants. 15% (8) of the 54 
gene carriers used cannabis in adolescence and had psychosis, and of the 148 gene 
carriers who did not use cannabis, 2% had a schizophrenia-like psychosis (3 people).
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Thus the number of schizophreniform individuals who used cannabis in adolescence and 
had the COMT variance was extremely small.
When Zammit et al. (2007) investigated COMT variance in a much larger sample (493 
participants), they did not find any significant difference in the associations between the 
onset of schizophrenia and cannabis use in those that had the VAL/VAL allele. 
Nevertheless, genetic evidence should not be totally disregarded. Genetic vulnerability 
may be the key to identifying eventually who among cannabis users is likely to develop 
a psychosis. It may be not just one gene variant, but several that can increase risk. Any 
consideration of the deficits of cannabis use will have to include genetic variation in 
pathways that influence both brain neurochemistiy and structure.
Genetic investigations need to be replicated but the effects of organic dysregulation of 
the dopamine system re-emphasize the importance of this system. It could be proposed 
that any factor that causes dopamine dysregulation would present as a vulnerability 
factor for the impact of the use of cannabis.
7.2 Schizoptvpy
Another vulnerability factor shown to mediate the impact of cannabis is a set of 
individual differences collectively termed psychosis-proneness or ‘schizotypy’. These 
consist of a continuum of personality characteristics and sub-clinical experiences related 
to psychosis, often drawing on the diagnostic features of schizotypal personality disorder 
(SPD) and are measured by a range of personality scales and interview schedules. 
Schiffman et al. (2005) reported that regular cannabis users are significantly more prone
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to schizotypal traits of cognitive and perceptual distortions as well as disorganization. 
Dumas et al. (2002) examined self-reported schizotypal traits among 232 healthy 
students and found that regular and past cannabis users evidenced higher schizotypal 
personality scores and magical ideation scores than those who had never used cannabis.
Verdoux et al. (2003) found that the effects of cannabis were modified by the 
individual’s vulnerability to psychosis -  “psychosis proneness.” This was assessed by 
Peters et al’s., 1999 Delusions Inventory (PDI-21) and the Community Assessment of 
Psychic Experiences (CAPE, Stefanis et al., 2001). Participants with high vulnerability 
(who had experienced at least one bizarre psychotic symptom or two non-bizarre 
psychotic symptoms over the last month) were more likely to report perceived hostility 
or unusual perceptions within 3 hours of cannabis intoxication than subjects with low 
vulnerability. The interpretation of these results is limited due to the small scale of the 
study. However, a more recent study tested 142 cannabis users both when acutely 
intoxicated and again drug free and 140 non users at the same time point (Mason et al., 
submitted). This clearly showed that people in the highest quartile on trait schizotypy 
experienced the greatest elevation in psychotic-like symptoms following acute cannabis 
use.
Barkus et al. (2005) report that high scoring schizotypes are more likely to report both 
psychosis like experiences from smoking cannabis as well as unpleasant after-effects 
associated with cannabis use (“amotivational syndrome” -  loss of drive, reduced 
attention, feeling slowed down). In a 4-year prospective study involving 2,400 people, 
Henquet et al. (2005) reported that the cumulative lifetime incidence of at least one
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psychotic symptom was 17.4% of adolescents and young adult cannabis users at follow- 
up and that cannabis use increased the risk for psychotic symptoms in a dose-wise 
fashion. In those cannabis users with personality traits characteristic of psychotic 
vulnerability (i.e. paranoid, schizotypy), 23.8% had at least two psychotic symptoms on 
follow up compared with only 5.6% of those without these traits.
13  The impact of life events on individuals* vulnerability
In Moore et al.’s (2007) systematic review of the effects of cannabis approximately 50 
different confounding factors were reported. The majority of these were related to family 
and peer relationships, adverse life events, mental health problems and other substance 
abuse. Van Os et al. (2002) report that urban living is another significant risk factor in 
the cannabis and schizophrenia association. It is hard to ignore the impact of significant 
adversity in mental health, not just in terms of the interpretation of every day 
experiences but the changes in neurobiological experience associated with distress.
7.4 Effects of age of first use
The age of first use of cannabis has been proposed to affect its impact in terms of 
subsequent psychopathology. Given that the age of first use of cannabis tends to be 
before an individual’s brain is fully developed, it is not surprising that the age at which 
cannabis use begins has been proposed to influence its impact on the person. Cannabis 
users under the age of 17 are 3.44 times more at risk for developing dependence 
symptoms than are users over the age of 26 (Dennis et al., 2002). MRI studies have
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shown that the frontal cortical connectivity is thought to still develop into the mid­
twenties (Toga et al., 2006). Given that there is a concentration of dopamine-sensitive 
neurons in the frontal lobes, it is tempting to view this critical developmental period as 
one of unusual vulnerability to the neurotoxic effects of cannabis.
In the Dunedin Birth Cohort Study (Arsenault et al., 2002), cannabis initiation by the age 
of 18 doubled, whereas initiation by 15 quadrupled the odds of subsequent 
schizophreniform disorder at follow-up aged 26 years. However, in a study using 
Swedish conscripts, no difference in risk of according to age at first use was found 
(Zammit et al., 2004). As Moore et al. (2007) notei the increased risk of psychosis from 
a younger age observed in the Dunedin study could indicate a greater cumulative 
exposure to cannabis rather than a sensitive period of exposure. Clearly, further 
investigation is needed before any conclusions can be drawn.
7.5 Length of chronic cannabis use
Solowij et al., (1995) reported that attentional impairments were progressive with the 
number of years of use but unrelated to frequency of use. Messinis et al. (2007) also 
found that the cognitive impact of cannabis use was greater in heavy long term users 
than in short term users. These results suggest that a chronic use of cannabis 
produces both short- and long-term cognitive impairments. However, as section 6.1.3 
reviews, in naturalistic studies, the duration of cognitive deficits of cannabis is still 
under question.
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7.6 Dose response
The effects of cannabis have been found to be dose related .in both recreational use and 
acute administration trials (Barnett et al.,1985; Pope et al., 1995; Curran et al., 2002; 
D’Souza et al., 2004). Bolla et al (2002) found that the cognitive deficits found in heavy 
cannabis users were related to the amount consumed. While acute administration of A- 
9-THC has caused transient psychotic symptoms, many of the naturalistic studies’ 
highest exposure categories were of weekly or bi-weekly consumption of cannabis. 
Clearly there are much heavier users and in 2003 the IMDU reported that 21% of users 
use daily (Atha, 2005). It is important to consider that there is a range of use and it is 
difficult to generalize effects.
The A-9-THC content of cannabis has changed over time. In the 1960’s, A-9-THC was 
isolated, identified and synthesized. "Skunk" cannabis, a cross-breed of Cannabis sativa 
and Cannabis indica, has become a more potent strain of cannabis, grown through 
selective breeding and usually hydroponics. Skunk cannabis potency ranges usually 
from 6% to 15% A-9-THC (in comparison to the 3-4% A-9-THC content in regular 
cannabis) and the average A-9-THC level in coffeehouses in the Netherlands is about 
18-19% (Niesink et al., 2005).
According to an analysis of drug samples seized by 23 police forces for the forensic 
science service in recent months, skunk now accounts for 81% of the cannabis in 
England and Wales, compared to just 15% in 2002 (King and Hardwick, 2008). The 
average A-9-THC content in ‘skunk’ in the UK has risen from 7% in 1995 and between 
16-19% today. In the recent police samples, the skunk examined ranged in A-9-THC
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potency from 4% to 46% (King and Hardwick, 2008). The increase in skunk is believed 
to be a result of users seeking a greater “high” and the availability of home hydroponic 
growing under intense artificial lights. According to the EMCDDA (2007), domestically 
produced cannabis cultivated hydroponically rose from 11% of the UK market in 1994 
to 63% in 2004. The quantity of cannabis plants seized more than doubled between 
2004 and 2005, from 95,103 to 212,971 plants.
Cannabis with higher A-9-THC potency leads to higher A-9-THC serum concentrations 
(Mensinger et al.,2006). A Dutch double-blind, randomized, placebo-controlled, cross­
over study of regular cannabis smoking males aged 18-45 years concluded that smoking 
cannabis with higher A-9-THC (reflecting the content levels of “Netherweed,” cannabis 
with 9-23% A-9-THC) leads to an increased of effect (Mensinger et al., 2006). This was 
particularly the case among younger or inexperienced cannabis smokers, who did not 
adapt their smoking behaviour to the higher A-9-THC content. Smoking cannabis with 
higher A-9-THC concentrations was associated with a dose-related increase of physical 
effects (such as increase of heart rate, and decrease of blood pressure) and impairments 
of psychomotor speed, concentration, motor control as well as drowsiness.
Human performance studies have usually relied on low-potency cannabis (4% A-9-THC) 
for determining THC-induced impairment. In Ramaekers et al., (2006) study, they 
found that effect sizes for performance impairments produced by A-9-THC 250 M-g/kg 
were relatively low but generally increased by a factor of two with a dose of A-9-THC 
500 M'g/kg. Use of higher doses of A-9-THC in controlled studies may offer a more 
reliable indication of A-9-THC induced impairment as compared to lower doses of A-9-
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THC that have traditionally been used in performance studies. Clinically, there is an 
absence of research into the recreational use of the higher potency skunk cannabis that 
dominates the UK market.
8 Clinical implications
This review has illustrated some of the mechanisms by which cannabis can contribute to 
prodromal symptomatology. Schizophrenia is undoubtedly a devastating and 
debilitating mental disorder. If cannabis can cause brain abnormalities that place an 
individual at greater risk for developing schizophrenia-like symptoms then this is an 
important issue that needs to be resolved. Although this review outlines the common 
links between cannabis and prodromal symptoms, we are far from fully understanding 
the changes in the endocannabinoid system, dopamine dysregulation and structural 
differences that have been found in individuals with diagnoses of schizophrenia and 
those who use cannabis. However, it is undoubted that further research is needed to 
determine the biological effect that cannabis has on the brain in people who do or do not 
go on to develop schizophrenia.
The focus of this review has been to highlight the common cognitive and 
neurobiological changes found as a result of cannabis use and in individuals identified to 
be in the prodrome but it is important to remember that the vast majority of individuals 
who use cannabis do not develop psychosis. Furthermore, any fully psychotic 
symptoms appear to be transient after the effects of the drug have worn off. In the 
Dunedin sample, 95% of 18 year olds who were using cannabis did not develop
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psychosis by the time they were 26 (Caspi et al., 2005). However, where the risk of 
psychosis is increased by 50-200% (Moore et al., 2007) in heavy users, there is a need to 
understand the mechanisms underlying the risk especially given that the estimated 
proportion of young people who have ever used cannabis in the UK is over 40% 
(EMCDDA, 2005).
The cognitive deficits caused by cannabis emulate some of those found in individuals at 
risk of psychosis and heavy users show deficits similar to prodromal symptoms. It 
seems as though cannabis use can put individuals in the “at risk” category but the 
vulnerability factors need to be investigated further. It could be that cannabis users who 
develop a transient psychotic episode subsequent to heavy use may have only a 
biochemical variant, such as low COMT activity, and thus higher dopamine synthesis 
that would potentiate the effects of cannabis and cause an acute psychotic reaction. 
With greater understanding of these vulnerability factors, public psycho-education 
concerning the effects of cannabis can be more effective. Murray et al.’s. (2004) 
research showed that up to 10% of the adult population is prone to paranoid thoughts or 
grandiose ideas and among those who smoke cannabis regularly, half may be tipped into 
psychotic delusions and end up needing treatment. Their study of 2,437 young people 
aged 14 to 24 found that of those who smoked cannabis regularly and had a pre-existing 
risk of psychosis, 50 per cent developed psychotic symptoms over the four- year follow- 
up period.
As a drug model for prodromal symptoms, cannabis does seem to mimic some of the 
cognitive and neurobiological changes reported in the prodrome and this is helpful in
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considering treatment strategies. However much of the research (on both acute 
administration and cannabis smokers) has been carried out with cannabis that is not 
reflective of the current market. In light of the dose-response findings, there is a need to 
have a greater understanding of the impact of higher potency skunk cannabis that 
accounts for over three-quarters of the cannabis currently consumed in the UK.
9 Future research
The transient psychotic symptoms induced using A-9-THC intravenously (D’Souza et 
al 2004) and cognitive impairments following acute oral consumption (Curran et al., 
2002) are not a reflection of the impact of cannabis consumed in the UK. In order to 
be able to generalise the results to normative consumption of cannabis (i.e. through 
inhalation), further research is needed to explore the symptoms in heavy users. The 
intravenous route of administration may have resulted in faster delivery and higher 
levels of A-9-THC than that typically achieved by recreational users. Indeed subjects 
generally reported that the A-9-THC effects were dissimilar to their previous 
experience with cannabis and participants were unable to titrate the effects by 
controlling dose or administration. Equally, research on the effects of cannabis with 
3-5% A-9-THC is not reflective of the cannabis smoked today. Given the dose- 
response findings, it would make sense for the impact of skunk to be greater than 
cannabis. Whether the higher potency skunk cannabis smoked today induces more 
basic symptoms of the prodrome is unknown and further research is needed. 
Furthermore, there are areas where we can learn from previous research in limiting 
confounding factors. In their systematic review of research on cannabis use, Moore 
et al (2007) found that only roughly half of the 35 studies they included had made
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adjustments for alcohol or other drug use and this needs to be considered in the 
future.
10 Conclusions
This review brings together research that illustrates how cannabis may contribute to 
different prodromal or UHR symptomatology. A major gap in the existing literature that 
this review has identified is that there has been no study directly assessing the full range 
of prodromal-like symptomatology in cannabis users. While intravenous 
administrations of A-9-THC have illustrated the psychoactive potential of cannabis, it 
does not provide a clinical picture. What is needed for a relevant clinical picture is 
research focusing on the full range of prodromal symptomatology with the cannabis that 
is consumed in the UK today i.e. skunk.
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Part 2
Empirical Paper 
Prodromal symptoms of schizophrenia in daily skunk users.
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Abstract
In the past decade meta-analyses have helped to establish a causal link between cannabis 
use and the onset of psychotic symptoms. Tetrahydrocannabinol (A-9-THC), the 
psychoactive component in cannabis, has been shown to induce transient psychotic 
experiences in healthy volunteers following acute administration. “Skunk” cannabis 
contains high levels of A-9-THC and now accounts for 81% of the UK cannabis market. 
However, no study has assessed the effects of this potent cannabis on recreational users. 
This study aimed to investigate whether heavy users of skunk show “prodromal” 
symptoms of schizophrenia - the symptoms of individuals at risk for developing 
psychosis. A total of 47 participants (27 daily skunk smokers and 20 matched controls) 
were assessed using the Schizophrenia Proneness Instrument, the Peters Delusions 
Inventory, the Dissociative Experiences Scale and the Oxford Liverpool Inventory of 
Feelings and Experiences. Cognitive assessments included measures of memory, 
fluency and superstition. Daily skunk users showed significantly more prodromal 
symptoms than controls and these included some of the cognitive deficits reported in 
individuals at high risk for developing schizophrenia. The study illustrates a profile of 
prodromal symptomatology in daily skunk users which appears to be differentiated from 
experiences under the influence of skunk. Dissociative symptoms were also observed in 
skunk users and these are not characteristic of the prodrome. These findings are 
discussed in terms of the clinical implications, the longitudinal research needed to 
monitor transition rate and the need for public information about potential effects of this 
drug which is currently consumed by over 2 million people in the UK.
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Introduction
Cannabis is the most widely used, illegal drug in the world (WHO, 2007). According to 
an analysis of drug samples seized by 23 police forces in recent months, “skunk” 
cannabis now accounts for 81% of the cannabis consumed in England and Wales (King 
and Hardwick, 2008). In May this year, the Home Secretary, upgraded cannabis to a 
Class B drug mainly due to concerns about both the dominance of skunk in the UK 
market and the association between cannabis use and psychosis. However, there is no 
published research into the psychological effects of skunk. Skunk is a more potent strain 
of cannabis composed of the flowering tops of unfertilised female cannabis plants. It is 
a combination of cannabis sativa and cannabis indica that is produced by intensive 
indoor cultivation methods. It is called skunk because of the pungent odour it emits 
while growing. The main psychoactive ingredient in cannabis is delta-9- 
tetrahydrocannabinol (A-9-THC) and the average A-9-THC content in ‘skunk’ in the UK 
has risen from 7% in 1995 to between 16 and 19% today (in comparison to the 3.5% A- 
9-THC content in traditional herbal cannabis). In the recent police samples, the skunk 
examined ranged in A-9-THC potency from 4% to 46% (Hardwick and King 2008).
Cannabis with higher A-9-THC potency leads to higher A-9-THC serum concentrations 
(Mensinger et al., 2006). Intravenous A-9-THC has been shown to induce transient 
psychotic symptoms (D’Souza et al., 2004) and cognitive impairments have been 
reported following acute oral A-9-THC consumption (Curran et al, 2002). However, it is 
hard to generalize these findings to recreational cannabis consumption. Systematic 
reviews and meta-analyses of recreational use have suggested that there is a causal 
relationship between cannabis use and psychosis (Arsenault, 2004; Moore et al., 2007;
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Semple et al., 2005). The most recent meta-analysis found an increased risk of any 
psychotic outcome to be approximately 40% in individuals who had ever used cannabis 
(pooled odds ratio= 1.41, 95%). This figure was elevated to a 50-200% increase in the 
risk for participants who used cannabis most heavily (Moore et al., 2007). Indeed, 
Moore et al. (2007) estimate that 14% of those currently diagnosed with schizophrenia 
in the UK would not have been if they had not used cannabis. The most recent British 
Crime Survey (Murphy and Roe, 2007) reported that 2.6 million people aged between 16 
and 59 years in England and Wales reported using cannabis in 2006/07. A survey of 
cannabis users carried out by the Independent Drug Monitoring Unit (IDMU) in 2000 
found that 21% of users smoked daily.
What is the evidence for a link between A-9-THC and schizophrenia?
The main psychological effects of A-9-THC stem from activation of the CB1 
cannabinoid receptor in the brain. When individuals smoke skunk the synaptic 
modulation by the brain’s natural cannabinoid, or “endocannabinoid,” system is 
disrupted; A-9-THC activates CB1 receptors and the cells are flooded. It has been 
hypothesised that a dysfunction in endocannabinoid signaling may be also associated 
with schizophrenia. For example, Giuffrida et al. (2004) showed that cerebrospinal fluid 
(CSF) from individuals suffering from schizophrenia contains significantly higher levels 
of the endocannabinoid, anandamide than CSF from healthy volunteers. They propose 
that endocannabinoids such as anandamide may enhance dopaminergic 
neurotransmission by increasing dopamine turnover.
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It has been shown that A-9-THC facilitates the release of dopamine in the brain 
(Voruganti, et al., 2001; Lupica and Riegal, 2005) and neuroimaging studies have 
illustrated heightened dopaminergic transmission in patients with schizophrenia. In the 
acute phase, psychotic patients show a higher synthesis of dopamine, heightened 
dopamine release in response to an impulse and a heightened level of synaptic dopamine 
(Kapur, 2003). Although there is evidence that other neurotransmitter systems also 
contribute to the psychopathology of schizophrenia (Holcombe et al., 2004), the first- 
line treatment of positive symptoms is invariably with antipsychotics that block 
dopamine D2 receptors. Thus neurobiological findings that link cannabis and 
schizophrenia are the endocannabinoid and dopamine dysregulation caused by A-9-THC 
which is also thought to occur in schizophrenia.
Cannabinoids also block hippocampal long-term potentiation (LTP), a potential 
substrate for learning and memory (Hoffman et al., 2007). LTP is a process by which 
the responsiveness of a neuron to a particular input becomes sensitized with repeated 
stimulation and is most prevalent in the hippocampus, an area of the brain important in 
memory (Ameri, 1999). Curran et al (2002) describe how memory impairment is a 
predictable effect of A-9-THC given the uneven distribution of cannabinoid receptors in 
the brain with the highest densities in the hippocampus, basal ganglia and cerebellum.
Kim and Thayer (2001) report that anandamide and other cannabimimetic drugs inhibit 
the formation of new synapses between hippocampal neurons in culture. Functional 
imaging studies also reveal that people with diagnoses of schizophrenia show reduced 
activation of the hippocampus in cognitive tasks like spatial navigation that are
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hippocampus dependent (Weinberger, 1997) and, of all cognitive impairments reported 
in schizophrenia, the most marked are in the memory domain (Saykin et al., 1991). 
Finally, A-9-THC also increases cortisol levels via activation of the CB1 receptor. High 
levels of this stress hormone have been associated with schizophreniform 
symptomatology as well as memory deficits (Walder et al., 2000).
Cannabidiol
Another cause for concern regarding the prevalence of skunk in the UK is that regular 
cannabis resin (accounting for only 14.6% of the UK market) contains approximately 
3.5% Cannabidiol (CBD) whereas skunk contains only 0.1% (Hardwick and King, 
2008). CBD is another cannabinoid in cannabis that has been identified as having 
neuroprotective factors (Iuvone et al., 2004) as well as anxiolytic effects (Leweke, 
2007). It has been proposed that CBD moderates the effects of A-9-THC (Morgan and 
Curran, 2008). In recent small-scale clinical trials, CBD has been effectively used as an 
antipsychotic for treatment resistant schizophrenia (Zuardi 2006: Leweke et al., 2007).
The Prodrome
The prodrome precedes the acute phase of a psychotic episode and extends from pre- 
morbid (“normal”) functioning to the onset of full symptoms of schizophrenia. It has 
been proposed that cannabis use leads to cognitive deficits of a similar nature to those 
seen in schizophrenia but of a lower magnitude (Solowij et al., 2007). Operationally, the 
prodrome is defined by duration of time, starting with the onset of decline in the baseline 
level of functioning and ending at the time when the criteria for a schizophrenia
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spectrum diagnosis is met (Yung, 1996). It is characterised by the progressive 
deterioration of functioning and emergence of sub-threshold psychotic symptoms.
If recognised prospectively, the existence of a defined prodrome offers the opportunity 
for early intervention. Early intervention for psychosis is crucial if services hope to 
prevent the psychological and social disruption that results from psychosis and the delay 
in such intervention is associated with poorer outcome (Johnstone et al., 1986; Loebel et 
al., 1992). From a neurobiological perspective, investigations into a drug like cannabis 
that causes dysregulation of dopaminergic neurotransmission might model the 
dysregulation reported in people with prodromal symptoms of schizophrenia. Drug 
models of those at risk of schizophrenia can be useful if a drug provokes features 
characteristic of the disorder. They are especially helpful in developing new treatments 
and our understanding of the pathophysiology of psychosis.
Operationally, two schools of thought predominate: the ‘ultra high risk’ (UHR) approach 
and the Basic Symptom Approach (Olsen and Rosenbaum, 2006). Schultze-Lutter et al. 
(2001) developed the Schizophrenia Proneness Instrument (SPI), a semi structured 
questionnaire which is based on the basic symptom concept. This is an integrative 
approach similar to the vulnerability-stress-coping model (Nuechterlein, 1992) that 
originates in the observation of deficits that were perceived by individuals with 
schizophrenia pre-psychotically, years before the first psychotic manifestation, or prior 
to relapses. Schultze- Lutter et al.’s basic symptoms are mild, often sub-clinical but self­
experienced disturbances of drive and affect, thought, speech, perception, proprioception 
and motor action as well as of vegetative functions. Klosterkotter et al. (2001) assessed
German patients for the presence of “basic symptoms” using the Bonn Scale for the 
Assessment of Basic Symptoms (BSABS) and in an average follow-up period of 9.6 
years, 49.4% of the cohort had developed schizophrenia (according to DSM-IV criteria).
Evidence for the schizophrenia prodrome in cannabis use to date?
Although no single study has systematically investigated whether cannabis users report 
experiencing symptoms identified in the prodrome, several research groups have studied 
the impact of the acute administration of A-9-THC or disturbances reported as a result of 
recreational cannabis use on a variety of measures which can be broadly mapped onto 
the six dimensions of the SPI-Adult version identified by Shultze-Lutter et al. (2004). 
These findings are brought together in Table 1.
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Table 1. Basic Symptom dimensions that have been reported as a result of the 
administration of acute A-9-THC and in recreational use of cannabis.
Basic Symptom Dimension 
(Schultze-Lutter et al., 2001)
Reported in 
administration of acute 
A-9-THC
Reported in 
Recreational 
Cannabis users
A. Affective Dynamic Disturbances Wadsworth et al., 2006., 
D’Souza et al., 2004
Lynskey et al., 
2004., Patton et 
al., 2002; 
Beautrais et al,
1999; Bovasso et 
al., 2001
B. Cognitive -  Attentional 
Impediments
Barnett et al., 1985; 
Musty & Kaback., 1995; 
Fletcher et al., 1996; 
Solowij et al., 1995;
D’Souza et al., 2004; 
Wadsworth et al., 2006
Pope et al., 1995: 
Solowij et al., 
1995; Barkus et 
al., 2005
C. Cognitive Disturbances Curran et al., 2002; 
D’Souza et al., 2004
Block and Ghoneim 
(1993)
D. Disturbances in Experiencing Self Mikuriya, 1998; Dumas et al., 
and Surrounding 2002
E. Body Perception Disturbances
F. Perception Disturbances D’Souza et al., 2004; Favrat et 
al., 2005; Mason et al., 2008
Verdoux et al., 
2003; Schiffinan 
et al., 2005; 
Morgan et al., 
2008., Barkus & 
Lewis, 2008
SPI A-A: Affective Dynamic Disturbances
The Affective Dynamic Disturbances in the SP1A range from changes in mood and 
emotional responsiveness to impaired tolerance to stress. These are changes that have also
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been reported in the acute administration of A-9-THC. In their 3- day, double-blind, 
randomized and counterbalanced study, the behavioural, cognitive and endocrine effects 
of 0,2.5 and 5mg of intravenous A-9-THC were characterized in 22 healthy individuals 
who had been exposed to cannabis but never diagnosed with a cannabis abuse disorder. 
D’Souza et al., (2004) found that acute A-9-THC caused blunted affect, reduced 
interaction with the interviewer and increased levels of the stress hormone cortisol. 
Cannabis use has also been associated with depression and anxiety (Patton et al., 2002; 
Lynskey et al., 2004). In a seven wave cohort study involving 1,601 students over six 
years (Patton et al., 2002), daily cannabis use in young women was associated with an 
over five-fold increase in the odds of reporting a state of anxiety (after adjustment for 
other substance misuse).
The negative changes in mood that are reported in the prodrome have also been found in 
research on the mood of cannabis users (Wadsworth et al., 2006; Bovasso, 2001). In 
Moore et al.’s systematic review (2007), their analysis of studies investigating an 
association between frequent cannabis use and depression revealed an adjusted odds 
ratio of 1.49 (95% Cl 1.15-1.95). Beautrais et al. (1999) reported that individuals with 
cannabis dependence (as diagnosed in DSM-IV) were at greater risk of suicide attempts. 
Lynskey et al. (2004) found that the twin who was cannabis dependent was more 2.5 to 
2.9 times more likely to have had a major depressive disorder, suicidal ideation and 
attempted suicide than their non-cannabis using twin. In their examination of the 
evidence of depression in cannabis users, Degenhardt et al. (2003) concluded that heavy 
cannabis use and depression are associated and evidence from longitudinal studies 
suggests that heavy cannabis use may increase depressive symptoms among some users.
However, as with Moore et al. (2007), they state that it is still too early to rule out the 
hypothesis that the association is due to common social, family and contextual factors 
that increase risks of both heavy cannabis use and depression.
SPIA-B: Cognitive -  Attentional Impediments
The cognitive attentional impairments in the SPIA include difficulties with attention, 
concentration and “thought energy.” In the SPIA, thought energy is defined as self- 
experience of initiating thoughts and an observable lack of goal orientation. Many 
studies have identified difficulties in concentration and attention as a result of both acute 
A-9-THC and recreational cannabis use. D’Souza et al. (2004) reported transient 
impairments in attention in their research on acutely administering A-9-THC and 
Solowij et al. (1995) found that the ability to focus attention and filter out irrelevant 
information was impaired in recreational cannabis users. Barnett et al. (1985) found a 
significant correlation between tracking errors in divided attention and A-9-THC plasma 
levels over 25 ng/ml among cannabis users assessed approximately 2 hours after 
smoking. Pope et al. (1995) tested the cognitive functioning of 64 heavy cannabis users, 
whom had smoked cannabis for at least 27 out of the previous 30 days. Heavy users 
showed significant deficits in sustaining and shifting attention.
In terms o f ‘thought energy,’ or ‘goal directed thinking,’ an “Amotivational Syndrome” 
amongst cannabis users described by McGlothin and West (1968) includes apathy and a 
diminished ability to concentrate but there is no specific mention of lack of thought 
energy. This may be a result of the semantics of the constructs being investigated but 
loss of motivation as a negative effect of cannabis was has been reported by Musty and
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Kaback (1995) and Barkus et al., (2005). However this “syndrome” of apathy and 
lethargy has been poorly documented in uncontrolled studies in the past and again, it is 
difficult to distinguish the effects of heavy cannabis use from those of poverty and low 
socioeconomic status, pre-existing personality factors and other psychiatric disorders.
SPIA-C: Cognitive Disturbances
The cognitive disturbances in the SPIA range from disturbances of indecision, thought 
interference, thought blockages, disturbance of speech and immediate recall. D’Souza et 
al (2004) reported that acute intravenous administration of A-9-THC produced 
symptoms including thought blocking, thought disorder, unusual thoughts, paranoia, 
suspiciousness, reduced spontaneity, and problems with memory. Block and Ghoneim 
(1993) matched heavy cannabis users and nonusers on the basis of their intellectual 
functioning before the onset of drug use and found that subjects who used cannabis 7 or 
more times weekly for at least 2 years showed deficits in verbal expression as well as 
selective impairments in memory. In fact, one of the most consistently reported 
behavioural effects of A-9-THC is a disruption in the free recall of newly learned 
information. Recall of items learned before cannabis use is generally not affected, 
suggesting that A-9-THC impairs learning and the acquisition of information but not its 
retrieval from memory (Curran et al., 2002; D’Souza et al, 2004). Curran et al., (2002) 
reported that oral A-9-THC impaired episodic memory and learning in a dose-dependent 
manner whilst leaving intact performance on tasks tapping perceptual priming and 
working memory.
SPIA-D: Disturbances in Experiencing Self and Surrounding
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The SPIA disturbances in experiencing self and surrounding consist of decreased 
capacity to discriminate between different kinds of emotions, emotional reactivity, 
thought pressure, referential thinking and changed perception of others. Cannabis use 
has been shown to decrease emotional reactivity and intensity of affect and is often 
use to self-medicate for this reason (Mikuriya, 1998). Cannabis use has also been 
shown to correlate with unstable ideas of reference or ‘subject-centrism’ (Dumas et 
al., 2002)
SPIA-E: Body Perception Disturbances
The body perception disturbances dimension focuses on unusual body sensations (e.g. 
numbness, stiffness, migrating sensations, shrinking, enlarging sensations that are not 
explicable by physical illness). I was unable to find any evidence of this in the 
literature with relation to cannabis use or of administration of A-9-THC.
SPIA-F: Perception Disturbances
The disturbances of perception included in the SPIA range from sensitivity to light 
and sound to somatopsychic bodily depersonalisation. Using an experience sampling 
method, Verdoux et al., (2003) found that in daily life, recreational cannabis use is an 
independent predictor of unusual perceptual experiences. Schiffman et al. (2005) also 
found that recreational cannabis users were more prone to perceptual distortions than 
individuals who had never used cannabis and this has been more recently confirmed 
in a study by Mason et al. 2008. In acute oral administration of A-9-THC, D’Souza et 
al. (2004) and Favrat et al. (2005) found increased depersonalisation and derealisation 
in healthy participants.
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Vulnerability Factors
A number of vulnerability factors have been suggested to mediate the effects of cannabis 
(for a review see Hunt, 2008) and some of these have implications for the present study. 
Schizotypy, age of first cannabis use, length and amount of cannabis use have all been 
highlighted in the literature as relevant variables.
Schizotypy
Psychosis-proneness or ‘schizotypy’ has been shown to mediate the effects of cannabis. 
Schizotypy is a continuum of personality characteristics and sub-clinical experiences 
related to psychosis. Verdoux et al. (2003) found that the effects of cannabis were 
modified by the individual’s “psychosis proneness.” This was assessed by Peters et al’s. 
(1999) Delusions Inventory and the Community Assessment of Psychic Experiences 
(CAPE, Stefanis et al., 2001). Participants with high vulnerability (who had experienced 
at least one bizarre psychotic symptom or two non-bizarre psychotic symptoms over the 
last month) were more likely to report perceived hostility or unusual perceptions within 
3 hours of cannabis intoxication than subjects with low vulnerability. These findings of 
the effects of schizotypy on psychotomimetic experiences as a result of cannabis use 
have been since replicated by Mason et al. (in press) and Barkus and Lewis (2008).
Life Experiences
In Moore et al’s (2007) systematic review of the effects of cannabis approximately 50 
different confounding factors were reported. The majority of these were related to family 
and peer relationships, adverse life events, mental health problems and other substance 
abuse. It is hard to ignore the impact of significant adversity on mental health, not just
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in terms of the interpretation of every day experiences but the changes in 
neurobiological experience associated with distress.
Age o f first use
The age of first use of cannabis has been proposed to affect its impact in terms of 
subsequent psychopathology, given that the age of first use of cannabis tends to be 
before an individual’s brain is fully developed. According to Dennis et al. (2002), 
cannabis users under the age of 17 are 3.44 times more at risk for developing 
dependence symptoms than are users over the age of 26. In the Dunedin Birth Cohort 
Study (Arsenault et al, 2002), cannabis initiation by the age of 18 doubled, whereas 
initiation by 15 quadrupled the odds of subsequent schizophreniform disorder at follow- 
up aged 26 years. However, in a study using Swedish conscripts, no difference in risk of 
according to age at first use was found (Zammit et al., 2004). As Moore et al. (2007) 
note, the increased risk of psychosis from a younger age observed in the Dunedin study 
could indicate a greater cumulative exposure to cannabis rather than a sensitive period of 
exposure.
Length o f use
Solowij et al. (1995) reported that attentional impairments were progressive with the 
number of years of use and Messinis et al. (2007) also found that the cognitive impact of 
cannabis use was greater in heavy long term users than in short term users. These results 
suggest that a chronic use of cannabis produces both short- and long-term cognitive 
impairments.
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Amount used: The effects of cannabis have been found to be dose related in both 
recreational use and acute A-9-THC or cannabis administration trials (Barnett et al., 
1985; Pope et al., 1995; Curran et al., 2002; D’Souza et al., 2004). Bolla et al (2002) 
found that the cognitive deficits found in heavy cannabis users were related to the 
amount consumed. Human performance studies have usually relied on low-potency 
cannabis (4% A-9-THC) for determining THC-induced impairment. Ramaekers et al. 
(2006) found that effect sizes for performance impairments produced by A-9-THC 
250 M-g/kg were relatively low but generally increased by a factor of two with a dose of 
A-9-THC 500 H'g/kg. It is difficult to generalize acute administration results to the 
general population and many of the naturalistic studies’ highest exposure categories 
were of only weekly or bi-weekly consumption of cannabis. If these effects have been 
reported in infrequent cannabis users, what effects would be found in daily skunk users 
exposed to higher concentrations of A-9-THC?
Present Study
While intravenous and oral administrations of A-9-THC have illustrated the 
psychotomimetic and cognitive effects of cannabis, these studies do not provide a 
clinical picture. The intravenous route of administration may have resulted in faster 
delivery and higher levels of A-9-THC than that typically achieved by recreational users. 
Indeed participants generally reported that the intravenous A-9-THC effects were 
dissimilar to their previous experience with smoked cannabis and were uneasy being 
unable to titrate the effects by controlling dose or speed of administration. On the other 
hand, research on the effects of cannabis with 3-5% A-9-THC is not reflective of the 
cannabis smoked in the UK today. As the Home Office Advisory Council for the
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Misuse of Drugs have recently stated, “further research is required to assess how users 
react to more potent forms” (Recommendation 16, ACMD, 2008, p38).
The present study aimed to determine the extent to which daily use of high potency 
cannabis (skunk) is associated with elevated prodromal-like symptomatology. It was 
hypothesised that daily skunk users would show greater prodromal symptomatology 
than controls who do not use cannabis. Furthermore it was predicted that symptoms 
would be most marked in those who smoked the most skunk and those who had been 
smoking the longest.
Following previous research into the cognitive impairments of recreational cannabis use, 
it was predicted that daily skunk users would perform significantly poorer on cognitive 
tasks assessing explicit and working memory and verbal fluency. It was also 
hypothesized that cognitive performance would correlate negatively with skunk 
variables (amount, frequency and years of use).
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Method
Power Calculation
There has been no previous reported research on either skunk users or on prodromal 
symptomatology in cannabis users. The power calculation was therefore based on 
results reported by Pope et al. (2003) on verbal fluency in cannabis users. The power 
calculations were performed using the online DSS Software 
(http://www.dssresearch.com/toolkit/sscalc/size_a2.asp). Group mean scores were 47.6 
(±11.3) cannabis users and 50.4 (±11.2) controls such that 21 participants would be 
needed in order to achieve a power level of 0.80 with alpha = 0.05. As this study was 
part of a larger drug/prodrome study at UCL, it was decided to use a minimum N of 20 
in order to parallel other arms of the research.
Design and Participants
An independent groups design was used to investigate prodromal symptoms in daily 
skunk users compared with non-using controls. As the study was part of a programme 
investigating the impact of different drugs on mental health, I was able to share controls 
with Lisa Monaghan (LM) from Royal Holloway D.Clin.Psy course (Appendix A).
Given the question over whether cannabis has a differing influence over people at 
differing developmental ages it was important to match participants for age. Equally, 
years of education have been shown to be a protective factor in mental health (Faraone 
et al. 2002) and it was important that groups were matched for this. Groups were also 
matched for gender to minimize effects of sex.
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Rather than both testing 30 control group participants, both LM and I tested 15 to create 
a control group of 30 as we were using the same test battery. This control group 
provided a control group for Suzanna Duffin’s DClinPsy research. Only 5 of LM’s 
controls who met the current study’s age criteria were included in the analysis. The test 
battery was piloted independently and then with LM to check for inter-rater reliability.
Participants were assessed either in the UCL Clinical Psychopharmacology Unit or in 
their own homes. They were required not to take any drug before testing and were asked 
to give a urine sample. Participants were first given a substance use interview before a 
battery of questionnaires and computer tasks. Skunk smokers were also given the 
Severity of Dependence Scale (Gossop et al., 1995) to assess their cannabis dependence. 
Participants were paid £15 for their time.
The study was approved by the UCL Graduate School Ethics Committee (Appendix B). 
Participants were recruited through contacts, a facebook group and then snowballing. 
All participants gave written, witnessed, informed consent (Appendix C). The inclusion 
criteria were that all participants were aged between 16 and 35 years old and could speak 
English fluently. Participants were screened (over the telephone or in person) to exclude 
those with (i) any history of psychiatric diagnosis and (ii) participation in other studies 
using any of the same tests. Due to limited recruitment time, participants were also 
excluded if they failed to attend the agreed testing time twice. For the “skunk” group, 
participants were required to have been smoking skunk every day for at least a year and 
were excluded if they took any other drug more than weekly. Daily skunk smoking 
participants also agreed not to smoke skunk on the test day. The non-drug using controls
were then recruited to match skunk users for age, years of education and gender. Once it 
was established that participants were eligible for the study, they were sent an 
information sheet by email (Appendix D).
Assessments
Tests were selected to assess the established features of the schizophrenia prodrome. 
Semi-Structured Interview
The Schizophrenia Proneness Instrument -  Adult version (SPIA - Schultze-Lutter et al, 
2004): This is a semi-structured interview used to assess participant’s schizophrenia 
proneness. The SPIA is an assessment tool that has been empirically developed to 
identify individuals in the prodrome. It has 6 main components: (A) affective dynamic 
disturbances, (B) cognitive attentional impairments, (C) cognitive disturbances, (D) 
disturbances in experiencing self and surroundings, (E) body-perception disturbances, 
and (F) perception disturbances. The SPIA was used to measure change that participants 
noticed since they had been smoking skunk (or change in the past year for controls). 
Participants were specifically asked about the experiences that were not drug induced 
i.e. experiences when they were not intoxicated (Appendix E). Where participants 
reported these experiences, they were asked for the frequency of these experiences in 
order to obtain a score (e.g. “less than once a week” =1 and “daily and persistent” = 6).
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Questionnaire Assessments
Oxford Liverpool Inventory o f Life Experiences (OLIFE 9: - Mason et al, 1995): The 
short form of the OLIFE questionnaire was used to assess psychosis-proneness, 
principally schizotypy. Its items were deliberately chosen to make it suitable for tapping 
psychotic characteristics in healthy individuals. This self-report questionnaire has 30 
yes/no questions that yield 4 factors: Unusual Experiences (an analogue of positive 
symptoms in schizophrenia including hallucinations and delusions); Cognitive 
Disorganisation (roughly corresponding to thought disorder); Introvertive Anhedonia 
(negative symptoms such as inability to derive pleasure from experiences and social 
withdrawal); Impulsive Non-conformity (relates to impulsivity and risk taking 
behaviour). Where participants report experiencing an item (e.g. “does a passing 
thought ever feel so real that it frightens you?”) they are given a score of 1 and these are 
added together to make totals of the 4 factors.
Peter’s Delusion Inventory (PDI-10: Peters et al., 1999): This self-report measure was 
designed to assesses delusional symptoms in the normal population with yes/no 
questions such as “Do your thoughts ever feel alien to you?” This was a 21 item 
questionnaire where participants also rated the degree of distress, preoccupation and 
conviction they had for each delusion reported on a 1-5 likert scale. Thus they received 
a total score (with a maximum of 21) and separate scores for totals of distress, 
preoccupation and conviction (each with a maximum score of 105).
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Life Experiences Survey (LES - Sarason et al.,1978): This is a self-report measure that 
taps positive and negative life events experienced over the previous year, and the 
perceived stress associated with those events. The 42 items were chosen to represent life 
changes frequently experienced by individuals in the general population and participants 
had the option of adding a further 4 events if they had not been previously listed. 
Participants rated each life event experienced on a 7-point scale ranging from -3 
(extremely negative) to +3 (extremely positive). If an event did not occur, the item was 
coded as 0. Every event that occurred is coded as one “life change unit” and the total of 
all positive and negative scores provided the LES total score. Positive and negative 
scores were summed separately, as was the number of items rated positive and negative.
The Beck Depression Inventory (BDI - Beck, 1978) and Spielberger Trait Anxiety 
Inventory (STAI - Spielberger, 1983) were used as measures of depression and anxiety. 
Although affect is measured as a factor in the SPIA, it was decided that more established 
questionnaire measures would be helpful to confirm levels of both depression and 
anxiety in participants. The BDI is a 21 item questionnaire with a maximum score of 63 
(0-3 for each item). Cut offs for the BDI are >10 = Not depressed, 10-15 = Mild 
Depression, 15-30 = Moderate Depression, 30+ = Severe Depression.
The STAI is a 20 item questionnaire with statements such as “I am cool calm and 
collected” where participants can rate “almost never,” “sometimes,” “often,” or “almost 
always” to yield a score of 1 -4.
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Cognitive Assessments
Prose Recall: Version 1 of the Rivermead Behavioural Memory Test (RBMT: Wilson et 
al., 1985) was used as a measure of verbal memory. Participants listened to a pre­
recorded short prose passage similar to a “news bulletin” on the radio. They were asked 
to recall the story immediately after presentation and again after a delay of 45 minutes 
filled by other tests. The story is divided into 21 “idea” units and recall is scored by 
allocating 1 point to each unit correctly recalled (or an exact synonym) and Y» a point for 
each partial recall of a unit or partial synonym.
Digit Span: Participants were asked to repeat strings of numbers as a measure of 
maintenance in working memory and then asked to repeat strings of numbers that they 
had heard backwards to assess manipulation as well as maintenance in working memory. 
When a participant failed to repeat or manipulate 2 strings, the assessment was 
complete. Digit Span is a subtest of the Weschler Adult Intelligence Scales (WAIS -  
III). For the purpose of this study, participants were given a score of 1 for each string 
they repeated correctly.
Verbal Fluency and Category Fluency (Benton and Hamsher, 1976): Participants were 
required to generate as many words as possible in 60 seconds which began with the 
letter F. Names of people, places were not allowed, nor were words which began with 
the same prefix. Category Fluency is another test used to measure participants’ speed of 
retrieval and level of executive function. Participants were required to generate the 
names of as many musical instruments as possible in 60 seconds. Each successful word
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or instrument awarded the participants 1 point so that a score of 15 on category fluency 
meant that the participant had generated 15 musical instruments.
Spot the word (STW: Baddeley et al, 1993): This test was used to estimate participants’ 
verbal intelligence. The spot the word consists of 60 item pairs, each of which contains 
one real word and one fake word and participants are required to identify the real word. 
Participants received one point for each successful word identification and these were 
then added for the total score.
Urine Samples
Each participant provided a urine sample in an EZ Split Key Cup. These allow for 
immediate analysis for recent use of cannabis, ketamine, cocaine, opiates, 
amphetamines, methamphetamines, benzodiazepines, barbiturates, methadone and 
tricyclic antidepressants.
Statistical analyses
All statistical analyses were performed using Statistical Package for Social Sciences 
(SPSS version 14.0). Group comparisons used ANOVA or t-tests where data was 
normally distributed or Mann Whitney for non-parametric data. Repeated measures 
ANOVA was used for prose recall data with immediate versus delayed as a within 
subjects factor. The alpha level was adjusted to 0.01 to minimize Type 1 error rate and 
Bonferroni statistic was used to accommodate for multiple testing. Correlations used 
Pearson or Spearman as was appropriate to the data.
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Results
A total of 52 daily skunk smokers expressed interest. Of these: 5 failed screening due to 
psychiatric diagnosis, 3 failed screening due to participation in a recent similar study, 2 
participants decided not to participate due to concerns about confidentiality and 6 due to 
worries about connections between the study and authorities (i.e. police or university 
examiners), 7 failed to attend their testing appointment two times. After receiving 
payment at the end of testing, 2 participants revealed that they did not smoke skunk 
daily and so were excluded. In all, 27 daily skunk smokers took part in the study (18 
male, 9 female) with a mean age of 21 years old (range from 16 to 29). 20 controls who 
reported no use of illicit drugs were recruited (11 male, 9 female, mean age of 23 years 
old ranging from 16 to 33).
1. Demographics
Table 2. Group mean (s.d) demographic information for the participants.
Daily Skunk smokers
N=27
Controls
N=20 F l,45
P
Age 20.93 (3.83) 23.35 (5.78) 2.99 0.91 (NS)
STW 45.85 (5.76) 48.25 (5.06) 2.20 0.15 (NS)
Years of Education 14.81 (2.02) 12.70 (7.14) 2.15 0.15 (NS)
A one way ANOVA showed that that there was no significant difference in age, years of 
education or pre-morbid IQ (Spot The Word (STW) Scores) between daily skunk 
smokers and controls. Of the skunk smokers, 9 were employed, 3 were unemployed and 
15 were students. Of the control participants, 14 were employed, 2 unemployed and 4
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were students. All were White British apart from 5 who were Asian (3 skunk, 2 
controls), and of the daily skunk users 2 were Chinese and 2 were Other European.
Drug Use
All of the daily skunk users had A-9-THC and A-9-THC only in their urine and none of 
the controls were positive for any drug. Of the daily skunk users, the mean years of use 
was 5.22 (±3.87) years (ranging from 1-15 years), the mean number of joints smoked 
per session was 2.31 (±1.10) (ranging from 0.5 to 4.5) and the mean number of days to 
smoke an eighth of an ounce of skunk was 6.78 days (ranging from 1.5 to 30 days). The 
mean severity of dependence score among daily skunk users was 4.3 (±2.98) which is 
higher than the dependence cut off score of 3 identified by Swift et al. (1998). Using 
this cut off, 17 (63%) of the daily skunk users were skunk dependent.
There was no significant difference in monthly alcohol consumption between the groups 
but daily skunk users smoked tobacco significantly more. 14 of the 20 controls had ever 
tried cannabis but had not used it in the previous year. Apart from skunk use, the main 
difference between groups in terms of current drug use was in MDMA consumption. On 
average, daily skunk users consumed MDMA once a month but no other drugs with such 
regularity. Table 3. shows the different drug use between groups.
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Table 3. Group mean (s.d.) for drug use and statistical comparison.
Drug Daily Skunk 
Users (N27)
Controls
(N20)
Mann-
Whitney
U
P
Alcohol days/month 13.88 (8.25) 10.30 (7.26) 211.00 NS
Alcohol yrs regular use 6.19(3.65) 6.83 (5.53) 269.00 NS
Alcohol units/ session 7.93 (3.86) 6.23 (4.41) 216.00 NS
Tobacco days/month 16.74(13.54) 3.35 (9.25) 127.50 p=0.001
Tobacco yrs regular use 2.85 (3.44) 1.45 (3.23) 166.00 NS
Tobacco amount/ session 4.81 (4.76) 1.90 (5.44) 133.50 p=0.001
MDMA days/month 1.1 (1.62) 0
MDMA yrs regular use 1.13(1.95) 0.18(0.67) 120.00 p<0.001
MDMA pills/ session 1.87(1.95) 0
Amph days/month 0.037 (0.19) 0
Amph yrs regular use 0.15 (0.77) 0.1 (0.44) 267.00 NS
Amph amount/ session 0.13(0.43) 0
Cocaine days/month 0.32(0.91) 0
Cocaine yrs regular use 0.39 (0.84) 0
Cocaine amount/ session 0.18(0.33) 0
Ketamine days/month 0.19(0.79) 0
Ketamine yrs regular use 0.019 (0.96) 0
Ketamine amount/ session 0.017(0.06) 0
2. Schizophrenia Proneness Instrument
A one way ANOVAs of the SPIA factors violated sphericity and so each factor was 
subjected to non-parametric (Mann-Whitney) analysis. All 6 SPIA factors showed 
highly significant group differences with daily skunk smokers having higher scores than 
controls (Fig. 2, Table 4.). There was no significant gender difference in SPIA scores.
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Fig. 1. Mean SPIA dimension scores for daily skunk users and controls (bars represent
standard errors)
I Daily Skunk Users
I Controls
Affective - Cognitive- Cognitive Self and Body Perception
Dynamic Attentional Surrounding Perception
Table 4. Group Mean (s.d.) scores on SPIA factors and statistical comparison.
SPIA Factor Group
Skunk Control
Mann-Whitney
-U
P
SPIA A- Affective Dynamic 
Disturbance
6.19(5.11) 2.30 (4.67) 128.50 0.002
SPIA B -  Cognitive Attentional 
Impediments
13.96 (6.63) 1.95 (2.19) 16.50 <0.001
SPIA C -  Cognitive 
Disturbances
16.07 (5.36) 2.00 (2.53) 4.00 <0.001
SPIA D -  Disturbances in 
experiencing self and 
surrounding
6.59 (3.58) 2.20 (3.24) 83.50 <0.001
SPIA E - Body Perception 
Disturbances
1.74 (2.60) 0.20 (0.89) 164.00 0.004
SPIA F - Perception 
Disturbances
3.52 (4.05) 0.95 (2.52) 30.50 <0.001
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3. Questionnaire Measures
One way ANOVAs were also used for the questionnaire measures. Daily skunk users 
had significantly higher total schizotypy scores than controls (Table 5). Of the OLIFE 
subscales, significant group differences were found in Non-Conformity, Cognitions and 
Unusual Experiences but not in Introverted Anhedonia. Daily skunk users reported 
more delusional thoughts on the PDI, they also scored higher on preoccupation, 
conviction and distress about these thoughts. Daily skunk users also reported 
significantly greater dissociative experiences than controls.
Table 5. Group mean (s.d.) scores on the OLIFE. DES and PDI. STAI. BDI. BIS and 
LES and statistical comparison.
Group
Skunk Control F (1,45) P
OLIFE
(Non Conformity) 4.67(1.75) 3.10(1.97) 8.251 0.006
OLIFE
(Introverted Anhedonia) 5.07(1.17)
4.73(1.28) 0.762 NS
OLIFE (Cognitions) 7.04 (2.41) 3.30 (2.23) 29.452 0.001
OLIFE
(Unusual Experiences) 4.85 (2.55)
2.40 (2.68) 10.150 0.003
OLIFE Total 16.26 (6.01) 8.20 (6.25) 19.93 <0.001
PDI Distress 15.04 (8.44) 7.90 (6.63) 9.80 0.003
PDI Conviction 17.78 (8.65) 11.70(10.62) 4.67 0.036
PDI Preoccupation 14.51 (7.51) 8.10(7.88) 8.05 0.007
PDI Total 6.19(2.60) 3.45 (2.84) 11.76 <0.001
BDI 11.59 (7.77) 5.70 (8.18) 6.32 0.016
STAI 46.16(4.43) 42.55 (6.64) 5.07 0.029
LES positive score 5.63 (5.64) 9.95 (6.22) 6.00 0.018
LES negative score -5.07 (6.82) -1.12(4.33) 4.99 0.031
LES items rated positive 4.11 (3.95) 2.74 (2.84) 1.68 NS
LES items rated negative 2.59(1.99) 3.21 (2.72) 0.80 NS
LES Total - 0.37 (9.28) 7.55 (6.53) 10.63 0.002
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Daily skunk users had significantly higher depression scores than controls overall. 37% 
of the daily skunk users met criteria for moderate clinical depression and a further 22%
20
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Fig 3. Depression in daily skunk users and controls
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for mild clinical depression (Fig. 4). Skunk users also scored higher on trait anxiety than 
controls. There was no significant group difference in the number of positive or 
negative life-events that participants reported in the life events survey. However, daily 
skunk users rated the life events that they had experienced in the previous year more 
negatively than controls and the controls had significantly higher positive scores. Daily 
skunk smokers scored significantly higher on the Barratt Impulsiveness Scale
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5. Cognitive assessments (Table 6.)
Table 6 Group Mean (s.d.) scores on Fluency and Digit Span and statistical 
comparisons.
Group F l,45 P
Skunk Control
Verbal fluency 
Category fluency 
Digit Span Forwards 
Digit Span Backwards
12.44 (2.65) 
16.74 (4.65) 
9.52 (2.45) 
6.11 (1.87)
18.15(6.85) 
18.30 (6.37) 
10.20 (2.24) 
7.45 (2.68)
15.653
0.944
0.953
4.072
p<0.001
NS
NS
0.05
Daily skunk smokers produced significantly fewer exemplars than controls in verbal 
fluency but not category fluency. Digits forwards showed no significant group 
differences but daily skunk users performed significantly poorer at digits backwards.
On Prose Recall, a repeated measures ANOVA showed a main effect o f group (Fj 45 = 
13.10, p=0.001), reflecting poorer recall by daily skunk users than controls on both 
immediate and delayed recall (Fig 4). There was also a main effect o f delay (Fj 45 = 
64.45 p<0.001) with both groups having better immediate than delayed recall (Fig. 4).
Fig 3: Prose recall scores by group and delay (bars represent standard error).
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6. Correlations
The OLIFE and PDI correlated with SPIA total (Spearman’s Rho: r = 0.74, p<0.001, and 
0.65, p<0.001, respectively). There was no significant correlation between skunk use 
variables (age of first use or years, quantity or frequency of use) and SPIA, delusions or 
schizotypy scores.
There was a negative correlation between digits backwards and years of regular skunk 
use (r= -0.496, p=0.009) and a negative trend between category fluency and the number 
of joints smoked per session (r= -0.46, p=0.015). Digit backwards scores correlated 
with SPIA-C (self report of cognitive disturbances: Spearman’s Rho = 0.553, p=0.01) 
Negative rating of life events correlated with BDI scores (r= -0.73, p <0.001). Among 
skunk users, those with higher total LES scores had higher SPIA scores (r = -5.30, 
p=0.004).
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Discussion
It is important to characterise the participants in this first study of daily skunk users. 
Their average age was 21 and they had been smoking on average for 5 years. Many 
(63%) met SDS criteria for dependence (and these criteria correlate highly with DSM- 
TR criteria for cannabis dependence, Martin et al., 2006). On average, the daily skunk 
users took MDMA once a month but no other drug with such regularity. The majority 
smoked an average of 2 splifTs in the evenings only and few found it hard to abstain for 
the day of the testing. Many said that they smoked to slow their thoughts, “to chill out” 
or because it “helps me handle stress.” Many of the students who smoked skunk seemed 
to have an insight into the cognitive effects and said that they would often stop smoking 
around exam time as they were aware of the impact that smoking skunk had on their 
ability to remember information.
Prodromal Findings
The findings of this study show a profile of prodromal symptoms in daily skunk users. 
As hypothesized, daily skunk users exhibited higher prodromal symptomatology than 
controls in all of the dimensions of basic symptoms. The basic symptom dimensions 
that were most pronounced in skunk users were cognitive disturbances and cognitive- 
attentional impediments. This is in line with previous research reporting cognitive 
impairments associated with recreational cannabis use (Solowij et al., 1998). The next 
greatest differences were in disturbances in experiencing self and surrounding and 
affective dynamic disturbances. The greater disturbances in self and surrounding in 
skunk users found in this study can be related to elevations in referential thinking 
following acute administration of A-9-THC reported by Dumas et al. (2002). The
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affective dynamic disturbances reported in skunk users also confirms previous research 
(Patton et al., 2002; Lynskey et al., 2004) and is further supported by the significant 
differences in depression and anxiety scores. Perception disturbances were the next 
most affected and disturbances in body perception were the least reported, although still 
significantly higher in skunk users in comparison with controls.
Questionnaire measures pointed to a similar pattern of results with higher schizotypy 
and delusions in daily skunk users (providing support for Verdoux et al., 2003; 
Schiffman et al., 2005; Barkus and Lewis, 2008; Mason et al., 2008). In terms of 
schizotypy, daily skunk users rated more unusual experiences, cognitive disorganization 
and impulsive non-conformity. Interestingly, they did not differ in introvertive 
anhedonia which may be reflective of the sample in that the majority were students who 
tended to smoke skunk socially in groups. Daily skunk users reported more delusional 
thinking and greater preoccupation and distress from these delusions. Their conviction 
in these delusions was also higher than controls.
It has been shown that acute cannabis smoking increases psychotic-like symptoms 
(Verdoux et al., 2003; Mason et al., in press) and this study shows that daily skunk users 
reported experiencing more psychotic like symptoms, or prodromal symptomatology. 
However, it is important to ask how does this “symptomatology” differentiate from 
acute cannabis intoxication in every day users? There is little dispute that cannabis 
intoxication can lead to acute transient psychotic episodes in some individuals 
(Arsenault et al., 2004). Yet, this study’s strength was in its use of the SPIA in that the 
interviewer always asked skunk using participants to differentiate between symptoms
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they had experienced when “stoned” and experiences that they had had when they were 
not under the influence of skunk. As interviewers, SD, LM and I had to keep cueing 
participants back to exclude drug experiences from their ratings. However, without 
longitudinal data it is hard to rule out whether these group SPIA differences were pre­
existing to skunk use.
Consistent with the latter suggestion, both Verdoux et al. (2003) and Mason et al. (in 
press) found that the psychotomimetic states following acute cannabis use were 
enhanced in individuals who were more psychosis prone (or schizotypal). In this study, 
daily skunk users with higher schizotypal traits had higher SPIA symptomatology. The 
significant correlation between SPIA and OLIFE scores either implies a personality 
element to the effects of the drug and/or an overlap in the constructs that these 
assessments tap. Either way, Mason et al. (in press) speculate that just as dopaminergic 
hyper-responsivity in schizotypal individuals has been observed (Soliman et al., 2007), 
cannabis-stimulated dopamine release may be the neurochemical basis of the elevation 
of psychotomimetic symptoms. The present study extends this possibility to include 
chronic as well as acute effects of cannabis use and the schizotypy findings support the 
continuum model of psychosis where high trait schizotypy is a vulnerability factor. This 
is the first time that schizotypy has been found to be associated with a clinical 
assessment of symptomatology.
As hypothesized, daily skunk users were also significantly more depressed and anxious 
than controls. Over half of the daily skunk using group met criteria for clinical 
depression and this is also reflected in the affective dynamic-disturbances reported on
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the SPIA-A and the correlation between negative rating of life events and BDI scores 
amongst daily users. Negative thinking in daily skunk users may have affected the way 
that they answered the Life Events Survey. Although the number of negative life events 
was not significantly different between the two groups, the rating of these life-events 
was. Skunk users rated their life events more negatively and controls rated their life 
events more positively.
Cognitive Findings
The present results confirmed the findings of previous studies investigating the impact 
of recreational cannabis use on memory, executive function and fluency (Ramaekers et 
al., 2006; Pope et al. 2001; Fletcher and Honey, 2006). Daily skunk users performed 
significantly poorer on prose recall. Prose recall is a reasonable predictor of real-life 
memory performance (Sunderland et al. 1986) and the poorer performance by daily 
skunk users is indicative of impairments in explicit memory. Daily skunk smokers were 
impaired on digit span backwards but not forwards indicating that it is the manipulation 
of information in working memory that is affected by skunk but not maintenance. 
Although the main group difference was in skunk consumption, it is important to look at 
these results in light of the many other variables that have been reported to affect 
memory.
The lower scores of the daily skunk users on verbal fluency replicated the findings of 
Messinis et al. (2006), Block and Ghoneim (1993) and Pope et al. (2003) with 
recreational cannabis users. Interestingly, daily skunk users were significantly impaired 
on verbal but not category fluency. With hindsight, the category “musical instruments”
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may have masked group differences given the association between cannabis use and 
music in this young age group.
Although there were no positive correlations of the skunk variables (years, quantity or 
frequency of use) with prodromal symptoms (SPIA), schizotypy, or delusions, there 
were associations between skunk use and cognitive measures. The more joints an 
individual smoked per session, the poorer they performed on category fluency and more 
years of regular skunk use was associated with poorer working memory (digits 
backwards). This suggests an accumulation of the effects of skunk and working 
memory. However, there was no evidence of a “critical period” of the effects of skunk 
in that there was no association between age of first cannabis use and either prodromal 
symptomatology or cognitive function.
How do cognitive impairments impact on prodromal symptomatology? If skunk causes 
dose-related cognitive impairments in memory and executive function, this may then 
contribute to how heavy daily users of skunk might interpret anomalous perceptual 
experiences as delusions, and other symptoms of the prodrome. From a 
phenomenological perspective, it is understandable how individuals who are finding it 
difficult to remember, sustain attention, communicate, monitor their behaviour and 
thoughts and plan and organise themselves might find it harder to process their 
experiences. It is not difficult to imagine how these deficits may lead to confusion, 
misattribution and distorted thinking. Memory deficits in individuals identified to be in 
the prodrome have been associated with poorer global functioning (Gschwandster et al., 
2003). If users do not attribute perceptual anomalies to poor memory, concentration, or
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visual disturbances caused by what they are smoking, they may be more likely to 
interpret these experiences to have meanings. Delusions are believed to be a cognitive 
effort to make sense of experiences. If skunk users have perceptual anomalies and other 
psychotomimetic experiences associated with the prodrome when they are not under the 
influence of the drug, this might become part of their normative experience with 
increasing tolerance to the effects of skunk and a hyperdopaminergic state. One could 
speculate that this may be a key mechanism in the link between cannabis and 
schizophrenia in vulnerable individuals.
Clinical Implications
The study has important clinical implications. The prodromal symptoms reported by 
daily users when not under the influence of skunk suggest a differentiation between 
acute skunk induced symptoms and early indications of a prodromal state. Daily 
users of skunk experience significant levels of prodromal symptomatology that is 
clearly separate to the acute effects of cannabis. In the past, naturalistic studies of 
recreational use have not distinguished between experiences when “stoned” and 
normal every day experiences. Given its widespread use in an age group of prime 
risk for psychotic disorders, the findings of skunk induced pre-psychotic state 
highlight substantial vulnerability in this group, and have implications for both the 
approach to skunk dependency and the funding of services. Nearly two-thirds of the 
sample were cannabis dependent (though a clinical cut-off is currently difficult) many 
are potentially at risk of psychotic and/ or affective disorder. Greater assessment and 
treatment options would seem a service priority in this area. If those cannabis 
dependent are in a pre-psychotic state, the NHS will need to accommodate this
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service need. Cannabis dependence is now second only to heroin as the primary 
substance of misuse in those newly seeking treatment for addiction in Europe 
(EMCDDA, 2007).
While not ruling out other clinical tools, the SPIA proved sensitive in the current study 
and undoubtedly has clinical value in identifying and monitoring prodromal symptoms 
in skunk users both in addictions services and early intervention services. If individuals 
who are smoking daily experience psychotic-like symptoms whilst not under the acute 
effects of the drug, it can be distressing and clearly put them at risk for developing 
psychosis.
The skunk users in this study appeared to have a level of insight into the effects that 
skunk had on them. Performance on the digit backwards task correlated with SPIA-C 
(self report of cognitive disturbances) indicating (i) a level of insight in the daily skunk 
using participants and (ii) a degree of accuracy of their self-reports. Impairment in 
insight is often reported in schizophrenia. It may be that those that do not have this 
insight are more likely to make the transition to full psychosis. Indeed, Schulze-Lutter 
et al. (2007) have recently investigated the relationship between subjective and objective 
cognitive function in the early and late prodrome. They report that participants in an 
early initial prodromal state were less impaired than those with a late initial state. 
Although there was no formal measure of participant’s insight, the correlations in skunk 
users’ subjective and objective cognitive scores may suggest that skunk users symptoms 
were on the milder end of the scale.
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The findings of symptoms identified to be “prodromal” in skunk users does not 
necessarily mean that skunk users are therefore in a developmental high risk group for 
developing psychosis. Many of these “symptoms” are signs and symptoms of other 
mental health disorders (bipolar disorder, severe depression) and it is important to put 
this symptomatology into context. However, many are indications of poor mental health 
and may well act as a vulnerability for the development of other psychopathology, 
indeed quite widespread levels of mild and moderate depression were indicated.
The results of this study have a number of implications at the individual level. A skunk 
smoker who presents with some of these prodromal symptoms will benefit from 
information about the association reported in this study. If these symptoms are 
distressing for them, they will benefit in support in ceasing their use of skunk, exploring 
the function of skunk for them and finding other ways to cope that do not have such 
potentially harmful side-effects. The results show that that individuals with cannabis 
dependence are likely to be suffering from depression and anxiety. As with many drugs, 
it may be that the acute effects of skunk allow users to avoid stress and anxiety in the 
short term but increase users experience of these in the long term. Furthermore, the 
deficits in memory and executive function found in the daily skunk users also have 
implications for clinical treatment of cannabis dependency. It is notable that 7 out of the 
52 who expressed interest in taking part in the study repeatedly failed to attend the 
testing appointments. This has implications for any treatment for those with cannabis 
dependency who are seeking help. If they can not plan and organize themselves in order 
to reach outpatient appointments, they may benefit from home treatment initially for any 
successful engagement.
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Future Research
This research has illustrated a broad profile of prodromal symptoms in individuals who 
use skunk every day but we do not know what percentage of these users may actually 
develop schizophrenia. A follow-up study would help us map this pathway and allow us 
to see if a change in SPIA prodromal symptomatology follows any change in skunk use 
over time. It would also allow us to learn if the impairments in working memory, 
episodic memory and fluency improve in those who reduce or cease their skunk use.
The duration of cognitive effects after cannabis users stop smoking is still under debate. 
Pope et al (2001) found that with abstinence of 28 days, long-term cannabis users 
showed no significant differences in cognitive tasks compared with non-using control 
groups. However, Lyons et al. (2004) and Bolla et al. (2002) found persistent cognitive 
deficits in decision making, memory, executive functioning, psychomotor speed and 
manual dexterity among heavy cannabis users who had been abstinent for 25 days. It is 
likely that participants were smoking less potent cannabis less frequently in these studies 
and a follow up skunk study would be more relevant to what is consumed today.
At present, it is difficult to generalize from this small sample of predominantly white 
British students. Replications with a more ethnically diverse sample would be useful. 
Furthermore, this study has brought up some phenomenological questions about skunk 
use which it would be helpful to address qualitatively. What motivates individuals to 
start using and maintains their use? Do users become tolerant to the effects? The level 
of insight that the skunk users in this study appeared to have may suggest a titration of
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the level of psychotomimetic experiences that individuals are able to cope with. What 
determines the titration of their skunk use and how does their use change over time? 
The answers to these questions will have implications for both treatment and public 
education campaigns.
Limitations
There are a number of limitations to this study. Firstly, some of the individuals who 
may have been most negatively affected by their skunk use did not take part in the study 
because (i) they were paranoid that I was an undercover police officer or (ii) they were 
unable to organize themselves to get to the department. Paranoia and impairments in 
executive function are both commonly reported in psychosis. Secondly, much of the 
data from this study relied on self-report. Although correlations between objective and 
subjective measures give support to the responses, under-reporting is common in 
substance misuse. Thirdly, the urine analysis provided an indication of recent use but 
did not allow us to quantify how much or what was in individual’s systems. 1 did not 
have a measure of the relative cannabinoid content of spliffs smoked which recent 
evidence (Morgan and Curran, 2008) has shown to have an impact on the psychotic-like 
effects of cannabis. Furthermore, “Skunk” has become a generic term for higher 
potency cannabis and there are many strains of varying potency. The study did not 
include a measure of the potency of the cannabis that each skunk user was using. 
Fourthly, as researchers, we were not blind as to which group participants were in. We 
had hypothesized and expected to see prodromal symptomatology in the skunk users and 
this may have biased our use of the SPIA. Fifthly, although the SPIA interview question
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sheet was piloted by us as researchers together, there was no formal inter-rater reliability 
in using the SPIA.
Finally, despite the strength of the findings, it is difficult to discount other potential 
differences between skunk users and controls that may influence their reporting of 
prodromal symptomatology. Although participants had to have not been given a 
psychiatric diagnosis to be included in this study, this does not exclude the possibility 
that some of the skunk users may have had a pre-existing mental health difficulty. This 
is a fundamental issue in a cross-sectional research design. As stated before, Moore et 
al. (2007) identified over 50 confounding factors in their review of the effects of 
cannabis on psychotic symptomatology and we did not have the time or resources to 
accommodate for these in this study.
Conclusions
This is the first study to investigate the effects of skunk. It has been carried out at a time 
when political anxiety about the effects of skunk is high and it is important to consider 
the findings of this study in context. Although daily skunk users did show more 
symptoms of the schizophrenia prodrome than controls, clearly this does not mean that 
they will go on to develop schizophrenia. Further research is needed to investigate this. 
Most cannabis users do not develop psychosis. There is a dearth of public information 
on the composition of skunk and the known effects of cannabis. The public need to be 
made aware that the minimal CBD content of skunk reduces the anxiolytic potential 
(that users in this study reported seeking) of the drug at the cost of more psychoactive 
and neurotoxic levels of A-9-THC. The cognitive impairments that were most
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pronounced in skunk users (deficits in working and episodic memory and verbal 
fluency) need to be shared with the public so that skunk users are aware of the potential 
impact of the drug upon their function and educational achievement.
This study supports the ACMD’s (2008) Recommendation 6 that a well resourced public 
education campaign alerting young people to the dangers of cannabis use needs to be 
developed. Further investigation into a drug that can cause prodromal symptomatology 
in users is undoubtedly needed. If 81% of 2.6 million people in the UK are using it and 
21% are using it daily, the potential implications for health costs are enormous. 
Longitudinal studies following the effects of skunk would help us understand the long 
term issues presented by this drug, and put us in a position to advise the public.
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Part 3
Critical Appraisal
138
Introduction
The following section provides a critical appraisal of the research, reflections on the 
recent reclassification of cannabis, future directions for skunk research and a personal 
reflection on the research.
Critical appraisal of the research
Before I started this research I had never heard of “the prodrome” or thought about 
observable pre-psychotic phenomena. I had recently read Mary Boyle’s book on 
schizophrenia (Schizophrenia: a scientific delusion) and I was far from convinced about 
the construct of schizophrenia let alone the concept of the prodrome. However, I 
appreciate the need for medical constructs for treatment development and I am keen to 
focus on preventative, early intervention, approaches to mental health. From meeting 
people who smoke skunk every day, it was clear that their presentations were distinctly 
different from “the norm” and I was curious to investigate this further.
Cannabis and schizophrenia
The association between cannabis use and schizophrenia has been investigated for 
decades and only recent meta-analyses have indicated that the relationship is probably 
causal. My review helped me to understand the neurobiological and cognitive reasons 
why this may be the case. Using the SPIA to investigate changes since skunk users 
began smoking the drug allowed us to begin to attribute prodromal symptomatology to 
skunk use. As controls were asked for changes in the past year, it allowed a control for
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“normative” change. This was particularly noticeable in the adolescent control 
participants who reported more changes in the previous year.
The prodrome as a concent
The notion of a developmental period of time before an individual develops frank 
psychosis is undoubtedly helpful in understanding schizophrenia and the early 
intervention, treatment and management of mental health. However, the prodrome is a 
vague construct with multiple pathways which are difficult to reduce to core criteria. 
Furthermore, the transition rates for the SPIA reported by Klosterkotter et al. (2001) 
were 49.4% and others have ranged from 34% (Yung et al., 2004), to 65% (Miller et al., 
2002). This leaves a large percentage of those showing prodromal symptoms who do 
not go on to develop diagnosable schizophrenia.
As a measure of prodromal symptomatology, the SPIA is one of the more sensitive 
instruments in comparison to other measures such as the Structured Interview of 
Prodromal Symptoms (McGlashan et al., 2001), the Comprehensive Assessment of At 
Risk Mental States (Yung et al., 2003) or the Initial Prodromal States (Simon et al., 
2006). It is important to be mindful that the prodrome is a relatively new construct that 
is still developing. The SPIA does not include perceptual abnormalities such as 
distortions, illusions and hallucinations which perhaps are closer to the development of 
frank psychosis and the level of insight in skunk users in this study may indicate that if 
they are prodromal they are more likely to be in the early initial prodromal state 
(Schulze-Lutter et al., 2007). It would be helpful to compare the different instruments
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with the skunk population to get an idea of their sensitivity (assuming that the prodome 
is a developmental period of time).
Participant Payment
Paying participants may have influenced this research in different ways. Firstly, those 
that were motivated by the financial incentive of £15 were more likely to be students and 
it subsequently had an impact on the sample. Secondly, payment may have had and 
impact on how much and what participants reported smoking. I was offering to pay 
individuals £15 if they had been smoking skunk every day for a year. Although I had 
urine analysis to check that they were smoking cannabis regularly, I had no way of 
determining (i) if this was skunk or (ii) if it was daily as the half life of cannabis in urine 
is prolonged. This became clear when two subjects at the end of two hours of testing 
revised the amount they reported smoking to 12 days per month. They knew that to be 
eligible for the research and the £15, participants needed to be smoking skunk daily. It 
was only in discussion with them at the end of the session that they admitted that they 
were not smoking daily and I had to exclude them from the analyses.
Exploratory Superstition Task
This study included the “Supertask” to investigate superstition and showed its potential 
usefulness as an objective measure. Skunk users saw patterns in the reinforced stimuli 
when reinforcement contingencies were totally randomised. The task was easy to use 
and participants enjoyed doing it. Although it assesses whether individuals saw patterns,
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it may have been helpful to control for individuals’ level of suggestibility as asking, “did 
you find any patterns?” may be a leading question.
Reclassification of cannabis
When the home secretary recently reclassified the class of cannabis, she ignored the 
expert advice sought by the Advisory Council on the Misuse of Drugs (ACMD, 2008). 
She was motivated by concerns about the prevalence of skunk in the UK market and the 
association of cannabis use with schizophrenia. However, she did this without the 
benefit of any research into the impact of skunk. In my view, this was a message to 
voters and not to cannabis users. Research by the Independent Drug Monitoring Unit 
(IDMU, 2007) has shown that many cannabis users do not i) understand the 
classification system or ii) know what classification cannabis is. The added cost of 
reclassification in terms of regulating drug traffic, sentences and fines would be far 
better invested in services and public education campaigns. In fact, the British Crime 
Survey showed that use declined between 20-25% in the past 5 years and cannabis was 
downgraded to a class C drug in 2004, (Murphy and Roe, 2007).
This study shows prodromal symptomatology in daily skunk users and I have concerns 
that the findings could be taken out of context and sensationalized without consideration 
of transition rates and follow-up studies. It is often the sensationalizing of research by 
the press that raises political pressure to make quick decisions like the one that Patricia 
Hewitt made in May 2008. The downgrading of cannabis in 2004 followed a press 
campaign to decriminalize the drug. Now, the attention of the press has moved to the 
“danger” of skunk and it has been reclassified. It is important to recognize that
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reclassification does not affect use because cannabis use did not go up when it was 
downgraded to Class C.
It is also important to put the impact of skunk on prodromal symptomatology in context. 
Countless variables have been proposed to influence the development of 
schizophreniform disorder and these are likely to mediate the influence of skunk. There 
are a number of other variables that would be helpful to include. For example, in their 
comparative study of prodromal symptoms, Hao-Yang and Yong-Guan (2001) reported 
that the most common prodromal symptom was social isolation and it would be 
interesting to see what influence social support has on prodromal symtomatology in 
skunk users. Equally, according to Sundquist et al. (2004), 34.6% cases of schizophrenia 
would be prevented if people were not bom and brought up in cities, compared to 5.4% 
of cases that would be prevented if people did not have parents or siblings who suffered 
from the illness.
Skunk: the future
A follow-up study would allow us to learn what happens to this group of daily skunk 
users in terms of prodromal symptomatology over time and how this compares to the 
transition rates reported by Klosterkotter et al. (2001). It would be interesting to know if 
the process of taking part in the research has an impact on their smoking behaviour. All 
of the skunk users wanted to be informed of the outcome of the study (and many were 
eager for feedback on their own results). For those who smoke less or cease smoking, 
does their prodromal symptomatology/ cognitive impairment get better?
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Skunk research would benefit from a large qualitative investigation into what influences 
people to begin smoking and what maintains their smoking behaviour. Investigation 
into the function of skunk use would help us explore the reasons behind its use. Eight 
out of the 30 skunk using group said that they smoked it “to calm me down” or to “slow 
down my thinking” whether these were “anxious thoughts” or “lots of thoughts.” If it is 
self-medication that people are seeking from skunk, there may be alternative remedies 
that have less dangerous potential and this would aid both treatment and public 
education campaigns.
The frequency of skunk use has decreased in the past decade. In 1995, 54.9% of users 
were smoking cannabis daily whereas in 2003, only 21% of users reported using daily 
(Atha, 2005). It would be helpful to understand qualitatively why users think this is. 
Some said that they “could not find regular traditional cannabis anymore so they had to 
smoke skunk.” Has the potency of cannabis lowered people’s frequency of use, do 
people titrate to a level they are comfortable with, and how does this change over time in 
terms of tolerance?
Further research into the physiological and neurobiological effects of skunk on the brain 
is also needed. Different combinations of CBD and A-9-THC in variations of cannabis 
may have different effects. There is a huge variety in the potency of different strains of 
skunk cannabis in the UK. In recent police seizures, the skunk examined ranged in A-9- 
THC potency from 4% to 46% (Hardwick and King, 2008). I had no way of measuring 
what participants were smoking in terms of CBD or A-9-THC content. The 
development of a cheap street version of gas chromatography would allow users to
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measure CBD and A-9-THC content of the cannabis they purchase and might give users 
more control over what they are smoking.
Personal reflection on the research
Motivation
I have always been interested in the effects of cannabis. When I was 19, a friend of 
mine who had smoked a vast amount of cannabis at a party accelerated his car into a 
tree. He survived to explain that he thought he could see a portal to another world and 
he knew that in order to get there he needed to be going as fast as possible. He will 
never play football again. On my clinical placements, I met clients who had also had 
cannabis induced psychoses and this further fuelled my curiosity.
Experience of Research
When I started this research I was apprehensive. My previous experience of research 
had involved an undergraduate BSc and a few audits. I was not confident about any 
statistical analyses it may involve and I saw the process of research on the course as a 
necessary hurdle that I would just have to face. I had always been more interested in the 
clinical side of training. It is only now when the research is coming to a close that I 
realize how much I have learned and how much 1 have gained from the experience. I 
now understand the process of carrying out research and this has given me confidence. 
This is undoubtedly the longest piece of work I have ever undertaken. It has been a 
daunting process and getting started was difficult. I spent far too long collecting papers 
for my literature review (it seemed easier to read other people’s work than to start
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typing) and I hadn’t appreciated that I could have easily written my methods section 
while I was recruiting. In hindsight, I realize that I had no real comprehension of the 
process of carrying out research like this. I hadn’t appreciated the stages of planning, 
recruiting, inputing, analyzing, thinking and reflecting and perhaps if I had understood 
these from the beginning it would have felt less overwhelming. For example, I hadn’t 
realized how long it would take to run the superstition task macros and hadn’t budgeted 
time for this. I’m sure that in comparison with many of my colleagues (who have 
already done PhD research) I was naTve in this way. Perhaps it just felt like a big jump 
from my BSc research 8 years ago.
My previous experience of using statistical theory and techniques was dry and not 
particularly exciting (another course hurdle). Until I owned my own data set, I didn’t 
know how enjoyable uncovering the results could be. Now I feel confident in using 
SPSS and I have enjoyed owning my data and exploring it. Previously I would have 
preferred to look for a post without a research component when I qualify whereas now it 
is one of the core criteria of any post that I apply for. I enjoy putting together and 
interpreting the results of my work and the satisfaction of finding quantitative evidence 
for my experience.
Practicalities
Despite previous literature highlighting difficulties in memory and executive function 
found in cannabis users, I had not fathomed the practicalities of this in terms of 
coordinating skunk smokers to arrive at the department for testing. It took a number of 
DNAs and late nights in the department to realize that a strategy was required. I learned
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that I needed to call to confirm the time and place that we had arranged more than once 
and I also sent emails with maps showing Goodge Street station and the UCL area. I 
then called people on the day to remind them and met them at the Goodge Street station 
and walk them to the department. The skunk users also took much longer to test. They 
had more to say on the SPIA and their processing speed seemed slower (although I did 
not get a chance to test this). Fortunately, the skunk users as a population generally 
were relaxed and pleasant to test.
Researcher Role vs Clinician
A number of participants were interested in the changes that they had noticed since they 
had been smoking skunk and were motivated to take part in the research in seeking 
reassurance that they were OK. In their eyes, they were coming to see a trainee 
psychologist who’d tell them whether or not they were “OK.” Where individuals were 
showing basic symptoms, it was difficult to know how much to encourage them to see 
their GP. For most, these symptoms were not distressing but where they were, I did 
encourage participants to visit their GPs. Some wanted to discuss this in detail and the 
boundaries between role as a researcher and as a clinician were hard to maintain when 
my instinct was to contain and support them in seeking professional help.
It was clear that the enterprise of answering questions about their skunk use and about 
the impact that this was having was a space for reflection that perhaps they had not had 
before. Many wanted specific feedback on their performance on the assessments which 
as a researcher I was unable to give. All wanted to know the outcome of the study and I 
have arranged to email a synopsis of the findings to everyone. In terms of an agency of
147
change, the process of reporting the negative effects of their skunk use was having a 
noticeable impact on participants and most were keen to discuss these in terms of 
thinking about decreasing or ceasing their use. As has been shown in the correlations 
between subjective and objective measures, most of the skunk users recognized the 
impact the drug was having on them. As already mentioned, many took breaks from 
smoking when they had exams or important events when they wanted their memories to 
function.
This made me question my role as a researcher. If skunk was having a negative impact 
on participants, did I have a responsibility to inform them and where did the boundary of 
my role lie? This raised an ethical issue for research as a whole for me. The participants 
did not sign up for clinical assessment; they offered to take part in research. While I was 
able to inform individuals that their scores were high and strongly advise them to see 
their GPs, it felt strange not having the clinical responsibility that I have become 
accustomed to on placement.
Being part of a team
My experience of this research as part of a team at UCL has been a very positive one. 
Although Lisa Monaghan, Suzanna Duffm and I were investigating different drugs, our 
battery of tests were the same. This provided a support that I do not think I can quantify. 
As researchers, Suzanna, Lisa and I were able to sound out ideas, approach 
methodological issues and the difficult practicalities of testing together. Furthermore, 
we were able to support eachother through lonely testing evenings in the department. It 
was not just as a team that we had support. I found huge confidence in the Clinical
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Psychopharmacology Unit (Professor Val Curran, Dr Celia Morgan and Dr Oliver 
Mason) and despite my limited research background, I felt enabled and supported. I 
never imagined that I would finish the course feeling capable of setting up independent 
research and now surprise myself in how interested I am in doing so.
Dissemination
From the literature review to the empirical investigation, this research has addressed the 
mechanisms linking cannabis use and prodromal symptomatology and investigated these 
in skunk users. This first investigation into the impact of skunk suggests prodromal 
symptoms and cognitive deficits in daily users. Undoubtedly, further investigation is 
needed but the confirmation of cognitive deficits and the finding of prodromal 
symptoms reported in skunk users motivate me to try to publish and disseminate the 
results. I feel a responsibility in contributing to the existing knowledge base and 
welcome constructive criticism which will allow this knowledge to grow. I feel that in 
this case, with knowledge comes responsibility and I would like to be involved in 
thinking and managing public education campaigns -  particularly to schools and in areas 
where children are most vulnerable. This way, on the basis of evidence, people can make 
informed decisions about using skunk, be aware of the potential negative impacts and of 
ways to seek help.
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Appendix A - Joint Thesis
Joint Thesis
This thesis was completed as part of a joint project to investigate the chronic effects of 
ketamine, cocaine and cannabis on prodromal symptomatology and cognitive 
dysfunction. Three separate theses were completed as a result of the joint project. 
They were entitled:
1) Prodromal symptoms in daily skunk users.
(Suzanna Hunt, Trainee Clinical Psychologist, UCL)
2) Do ketamine users show psychotic symptomatology and cognitive dysfunction 
associated with the pre-psychotic state of the psychoses?
(Suzanna Duffin, Trainee Clinical Psychologist, UCL)
3) Chronic Cocaine use and prodromal symptoms of schizophrenia 
(Lisa Monaghan, Trainee Clinical Psychologist, Royal Holloway)
All trainees completed the design of their individual theses together, as some 
participants were shared. Below is an outline of the contribution of each individual 
member to the joint project:
1) Suzanna Hunt: Completed the semi-structured interview protocol for the SPI-A 
alongside Suzanna Duffin. Piloted full assessment battery with 1 skunk user and 2 
controls. Collected data as outlined in her methodology for 27 daily skunk users and 
15 controls (reporting no illicit drug use). Data for 5 additional control participants 
was gained from control data gathered by Lisa Monaghan.
2) Suzanna Duffin: Completed the semi-structured interview protocol for the SPI-A 
alongside Suzanna Hunt, and created the scoring sheet for the SPI-A. Collected data as 
outlined in my methodology from 21 frequent and 20 infrequent ketamine users. Data 
for 20 matched control participants was selected from control data gathered by 
Suzanna Hunt and Lisa Monaghan.
3) Lisa Monaghan: Piloted the SPI-A with recreational drug users. Collected data as 
outlined in her methodology for 30 cocaine users and 15 controls (reporting no illicit 
drug use). Data for 15 additional control participants was gained from control data 
gathered by Suzanna Hunt.
Appendix B - Ethical Approval
SPECIAL NOTE
THIS ITEM IS BOUND IN SUCH A 
MANNER AND WHILE EVERY 
EFFORT HAS BEEN MADE TO 
REPRODUCE THE CENTRES, FORCE 
WOULD RESULT IN DAMAGE
JCL RESEARCH ETHICS COMMITTEE
Amendment Approval Request Form
1 ID Number:
0052 / 001
Nam e and A ddress of Principal Investigator:
Professor H Valerie Curran
2 Project Title:
T h e  d e t e r m i n a n t s  a n d  p s y c h o lo g ic a l  c o n s e q u e n c e s  o f  k e ta m in e  u s e
Information a b o u t the am endm ent:
(a) Is the amendment purely administrative? Yes □ N0 □N/A
(b) Has the Participant Information Sheet/Consent Form been changed as a result of the 
amendment? ___  ___
0  Yes I I No l | N/AIf yes, p lease enclose a copy.
Sum m arise th e  i s s u e s  contained in the am endm ent:
The amendment is for a spin-off study from the main project which has suggested that some 
ketamine users exhibit ‘prodromal’ (psychosis-pronesness) symptoms. To investigate this 
formally, we will be administering the Schizophrenia Proneness Inventory, which is a semi- 
structured interview measure that examines a range of experiences phenomenologically related to 
schizophrenia. W e will also be adding some straightforward tasks that tap cognitive changes in 
schizophrenia (superstition, context modulation, and memory).
We will compare ketamine users with 2 groups of other drug users by splitting the group of 
polydrug users in the main study into those who use cannabis and those who use stimulant drugs. 
The rationale for this comparison is that i) cannabis use is a known trigger of psychosis-like 
symptoms and ii) drugs that are primarily dopamine-releasers (like stimulants) can also induce 
psychotic symptoms.
There will be four postgraduate students (Doctorate in Clinical Psychology) carrying out this study: 
Suzanna Duffin, Suzanna Hunt and Lisa Monaghan.
To a ssess  the additional participants, we request an extension of the ethical approval of the project 
until December 2008.
5 | P lea se  g ive any o th er information you feel may be n ecessary:
Signature^6TNPrincipal I ^stigator:
FOR OFFICE USE ONLY:
Date o f Subm ission:
16 February 2007
Amendments to the proposed protocol have been . . j f o Q & y p j t f & l .  by the Research Ethics 
Committee I '
Appendix C - Consent Form
SUB-DEPARTMENT OF CLINICAL HEALTH PSYCHOLOGY
UCL PSYCHOLOGY
TfffiT
Consent Form
CONFIDENTIAL
T h e  d e te r m in a n t s  a n d  p sy c h o lo g ic a l c o n s e q u e n c e s  o f  k e ta m in e  u s e
Investigators: Dr. Celia Morgan, Suzanna Duffen, Suzanna Hunt, Lisa Monaghan, Leslie 
Muetzelfeldt, Prof. H.Valerie Curran
Please complete the following: delete as neccessary
1. Have you read the information sheet ? YES / NO
2. Have you had an opportunity to ask
questions and discuss this study ? YES / NO
3. Have you received satisfactory answers
to all your questions ? YES / NO
4. Have you received enough information
about this study ? YES /NO
5. Which investigator have you spoken to
about this study ? ........................................................
6. Do you understand that you are free to withdraw from 
this study:
* at any time YES / NO
* without giving a reason for withdrawing YES / NO
7. Do you agree to take part in this study ? YES/ NO
Signed............................................................  Date.................... ....
N a m e  (p le a s e  p r i n t )   ....................................................................................
Investigator.
Appendix D - Information Sheet
SUB-DEPARTMENT OF CLINICAL HEALTH PSYCHOLOGY
UCL PSYCHOLOGY
iiiii
VOLUNTEER INFORMATION SHEET
The determinants and psychological consequences of cannabis use 
Investigators: Suzanna Hunt, Suzanna Duffin, Lisa Monaghan, Leslie Muetzelfeldt, Dr. 
Celia Morgan, Prof. H.Valerie Curran
Purpose of the study:
To determine the long term effects of recreational skunk use
INFORMATION LEAFLET FOR VOLUNTEERS
You are being invited to take part in a research study. Before you decide, it is important 
for you to understand why the research is being done and what it will involve. Please 
take time to read the following information carefully and discuss it with friends and 
relatives if you wish. Ask us if there is anything that is not clear or if you would like 
more information. Take time to decide whether or not you wish to take part.
WHAT IS THE PURPOSE OF THE STUDY?
We are interested in the effects of recreational drug use on mental functioning and 
mood. We also wish to examine whether mental functioning and mood changes as use of 
skunk and other drugs changes over time.
SOME BACKGROUND TO THE RESEARCH
Many drugs have long term effects; for instance people who drink lots of alcohol often 
find their memories are not as good as they were. This can often be affected by factors 
such as the length of time they have been drinking and the quantity that they drink. The 
present study aims to find out what the long-term effects of using recreational drugs, in 
particular skunk, may be, by examining how any changes in cognitive functioning are 
related to changes in drug use.
WHAT WILL BE STUDIED?
We will be looking at memory, problem solving and concentration as well as mood and 
mental state in people who take skunk, people who take other drugs but not skunk and 
people who do not take any recreational drugs.
HOW WOULD I BE INVOLVED IF I AGREED TO TAKE PART?
If you do decide to take part you will be given this information sheet to keep and be 
asked to sign a consent form. If you decide to take part you are still free to withdraw at 
any time and without giving a reason.
If you agree to participate, on the testing day you will come to the Psychopharmacology 
Laboratories at UCL or if agreed, the experimenter may come to your home. The 
experimenter will then record some information about your current drug use and patterns 
of use, including giving a hair and urine sample, and you will take part in an interview 
about your mood and mental state. Altogether this will last for approximately half an 
hour. You will then complete some computer-based cognitive tasks, which will last for 
approximately 1 hour, with space for a break if you should need one. You will then be 
paid for participation.
CONFIDENTIALITY
Any information collected about you will be held in accordance with the 1998 Data 
Protection Act. All the information that is collected about you during the course of the 
research will be kept strictly confidential. Your results will have your name and any 
other details about you removed first so that you cannot be recognised from them.
I f  y o u  r e q u i r e  f u r t h e r  in fo r m a t io n  p le a se  a s k  S u z a n n a  H u n t
Thank you for reading this leaflet and we hope that you will be able to take part in the 
study.
Y o u  d o  n o t  h a v e  to  t a k e  p a r t  in  th e  s tu d y  i f  y o u  d o  n o t  w a n t  to . I f  y o u  d e c id e  to  
t a k e  p a r t ,  y o u  m a y  w i th d r a w  a t  a n y  t im e  w ith o u t  h a v in g  to  g iv e  a  re a so n .
All proposals for research involving human subjects are reviewed by an ethics 
committee before they can proceed. This proposal was reviewed by the UCL Committee 
for the Ethics of non-NHS Human Research.
Appendix E -  SPIA Interview Schedule
SCHIZOPHRENIA PRONENESS INSTRUMENT -  ADULT 
VERSION (SPI-A) INTERVIEW SCHEDULE
I would like to ask you a number of questions about some of your experiences since you 
started smoking skunk. I need to emphasise that I am not asking you about experiences 
you may have had WHILST you were on the drug or whilst you were coming down 
from the drug, BUT rather I’m interested in your everyday experiences.
A) Affective-dynamic disturbances
A l:  I m p a i r e d  to le r a n c e  to  c e r ta in  s t r e s s o r s
G E N E R A L  Q U E ST IO N
- Do you think your ability to tolerate stress has decreased since you started smoking skunk? So 
specifically I am asking about stress that involves unusual or new things, social everyday 
situations (like having a chat or watching TV), and working under time pressure?
IF  Y E S
OK -  I’m going to ask you a few more specific questions about this now 
G O  T O  A l . l
IF  N O
move to A2
A l . l  I m p a i r e d  to le r a n c e  f o r  u n u s u a l ,  u n e x p e c te d  o r  sp e c if ic  n o v e l d e m a n d s
• Can you handle new, unusual or suddenly occurring tasks as well as before you started 
smoking skunk? Things like a specific demand at work or a visit to the local authorities, 
or moving or having a holiday?
• Do you feel like you can’t handle it when something unusual or unplanned happens, so a 
situation like this would be too exhausting or too much?
• Do unusual or unplanned things happening cause feelings like being nervous, tense, 
restless, or dizzy, or problems with sleeping?
R a t in g :  F r e q u e n c y  I
I f  n e e d e d :  E ffe c ts  o n  p e r f o r m a n c e  b e h a v io u r  (V I)
A 1 .2  I m p a i r e d  to le r a n c e  f o r  c e r ta in  so c ia l e v e ry d a y  s i tu a t io n s  (w h ic h  a r e  so c ia lly  
n e u t r a l )
• Can you still tolerate being around others or having conversations with others since 
you started smoking skunk?
• Can you still do things like go to the shops, go on public transport, or go to public events 
as comfortably as you did before you started smoking skunk?
• Do any of these situations cause feelings like nervousness, tenseness, restlessness, heart 
beating, sweating, pain or concentration difficulties?
• Do you sometimes feel like watching or hearing things like the radio or TV is just too 
much for your senses, like its exhausting or you can’t handle it?
R a t in g :  F r e q u e n c y  I
I f  n e e d e d :  E f fe c ts  o n  p e r f o r m a n c e  b e h a v io u r  (V I)
A 1 .3  R e d u c e d  a b i l i ty  to  w o r k  u n d e r  p r e s s u r e  o f  t im e  o r  r a p id ly  c h a n g in g
d i f f e r e n t  d e m a n d s ,  th e r e f o r e  s t a r t  to  a v o id  s u c h  s i tu a t io n s  o r  b e  m o re  r ig id  
in  t h e i r  b e h a v io u r
(NOT A8.4 which is more to do with a cognitive deficit in not being able to divide 
attention)
• Are you as able to deal with having several different things to do at once and working 
under time pressure, as you were before you started smoking skunk?
• Does having multiple tasks to do, or being in time pressured situations make you more 
nervous and agitated now? Do you find you have problems with concentration during 
such situations, or you experience nervousness, heart racing, restlessness, sweating or 
pain?
• Do you have to avoid being rushed since starting to take skunk?
R a t in g :  F r e q u e n c y  I
I f  n e e d e d :  E f fe c ts  o n  p e r f o r m a n c e  b e h a v io u r  (V I)
A2 Change in mood both positive and negative (usually low or 
emotionless mood -  always unrelated to external events) AND 
emotional responsiveness
N O T  b r ie f  o r  tra n s ie n t change; N O T  A3 w hich  is to  do  w ith  activ ities a n d  in te rests  
lo sing  th e ir  positive  im p a c t on  c lien t
• Has your GENERAL mood changed overall since you started smoking skunk -  for 
example has it become more negative and low?
• Can you be as happy, laugh and enjoy things as much as you used to?
• Do you think your feelings have become less intense since you started smoking skunk?
• Do you think you have become less emotionally involved in things since you started
smoking skunk? Is this generally the case or just with certain things?
Rating: Frequency I
If needed: Subjective burden (IV), Effects on quality of life (VI), Areas of life
(VIII)
A3 Decrease in positive emotional responsiveness towards others.
(d ec reased  feelings o f  love, affection , sym pathy , p ity  a n d /o r  in te re st to w ard s  o th e r  
pe rso n s  o r  p rev iously  im p o r ta n t activ ities/hobbies. D O  N O T  score th is  item  if  
d e c rea se  in  responsiveness &  hobbies, e tc  is a  coping beh av io u r to  a decreased  
s tre ss  to le ra n c e  w ith  re sp ec t to  everyday  s ituations)
• Are you still as interested and emotionally involved in things you like to do - your
hobbies etc. -  as you were before you started smoking skunk?
• Do you still feel the same affection and/or interest for your relatives and friends as 
before you started smoking skunk?
Rating: Frequency I
If needed: Subjective burden (IV), Effects on behaviour (VI)
B) Coenitive-Attentional impediments
OK -  I’m now going to ask you about your thinking and attention abilities since you 
started smoking skunk.
B1 Inability to divide attention
(d ifficu lty  sp littin g  a tte n tio n  betw een  stim uli w hich  re q u ire  d ifferen t senses; 
p ro b le m s  switching a tte n tio n  n o t sco red  here)
• Can you do two things at the same time as easily as before you started smoking skunk? 
So for example, can you write notes whilst you talk to someone on the phone, or can 
you do the cooking AND talk to someone at the same time?
• Do you have to just do one thing at a time to make sure it gets done properly?
Rating: Frequency II
If needed: Subjective burden (IV), Effects on B&P (VI)
B2 Feeling overly distracted by stimuli
(o n e 's  a tte n tio n  is ra ised  randomly by  ex te rn a l s tim uli you d o n ’t  w a n t to  a tte n d  to); 
N O T  d ifficu lties in ten tio n a lly  sp littin g  a tten tio n  -  th is  is scored in B1 o r  any  s o r t o f  
cogn itive  in te rfe re n c e  th a t  occu rs  w ith o u t th e  p resence o f  an e x tern a l s tim u lus (C2 
& D 3)
• Do you think that since you started smoking skunk, everything around you catches your 
attention, even if you don’t want it to?
• Is your thinking interrupted, aimless or disturbed by being too aware of other things? For
example, have you ever found that you can’t focus on something because other things
around you have randomly taken your attention away?
Rating: Frequency II
If needed: Subjective burden (TV), Effects on B&P (VI)
B3 Difficulties concentrating
(N O T  because  o f  an y  o th e r  cog d is tu rb a n ce  such as in trud ing  though ts  (C2) 
obsessive/ p e rsev era tio n  o f  th o u g h ts  (O l) , th o u g h t p ressure  (D3), th o u g h t blocking
(C 3), d is tu rb a n c e  o f  co m p reh en sio n  o f  v isual o r  a u d ito ry  m a te ria l (C4), a t tn  
d is tu rb a n c e s  (B l, B 2 ,0 7 ) lan g u ag e  p rob lem s; could be because o f  m em ory  
d is tu rb a n c e s  -  sco re  th is  in  C .1 .8 ./9  too)
• Concentration problems are when you find it difficult to keep your mind on a task for 
several minutes, like watching TV or reading, or making a cup of tea. Thinking about 
that, do you think you have had more difficulties concentrating since you started 
smoking skunk?
• Do you know the reasons for your concentration problems -  for example, are they 
because of your thoughts racing or are they triggered by work, or difficulties 
understating what others are saying to you?
• When you are concentrating on something, do thoughts about other things come into 
your mind? Are your thoughts suddenly gone or do you simply loose the train of 
thoughts? Is it always things like that which cause your difficulties concentrating?
• Can your concentration problems occur at any time or just when you feel quite stressed?
R a t in g :  F r e q u e n c y  I
I f  n e e d e d :  S u b je c t iv e  b u r d e n  (IV ) , C o p in g  (V ), E f fe c ts  o n  B & P  (V I)
B4 Difficulties to hold things in mind for less than half an hour
• Have you noticed you have more difficulties keeping things in mind, even for half an 
hour, since you started smoking skunk? For example, after you have read something or 
watched something on TV, can you still remember the main content half an hour after?
R a t in g :  F r e q u e n c y  I I
I f  n e e d e d :  S u b je c t iv e  b u r d e n  (IV ) , C o p in g  (V ), E f fe c ts  o n  B & P  (V I)
D o  n o t  a s k  B 5  i f  c r i t e r i a  B 3  s c o re d  (N O T E : i f  C 4  o r  C 5  a r e  s c o re d , th e n  s c o re  fo r
B 5  is  in v a l id  -  see  p a p e r  f o r  e x p la n a t io n  w h y )
B5 ‘Slowed-down’ thinking
(g en e ra l co m p la in t th a t  th in k in g  h as  becom e slow er a n d  h a rd e r ; w hich m igh t 
o c c u r  A S A  R E S U L T  o f  o th e r  cognitive d is tu rbances)
• Do you sometimes feel that your thinking has become slower, harder or more sluggish 
since you started to take skunk?
• For example, is every answer in this interview a real effort?
R a t in g :  F r e q u e n c y  I I
I f  n e e d e d :  S u b je c t iv e  b u r d e n  (IV ) , C o p in g  (V ), E f fe c ts  o n  B & P  (V I)
B6 Lack of 'thought energy' or goal-directed thoughts
(N O T  loss o f  p e rfo rm a n c e  o f  au to m atica lly  p e rfo rm ed  skills - O i l )
• Do you think you sometimes lack the strength or energy to think or speak, since you 
started smoking skunk?
• Do you sometimes have difficulties developing your own ideas or planning things, such 
as cooking?
R a t in g :  F r e q u e n c y  I I
I f  n e e d e d :  S u b je c t iv e  b u r d e n  (IV ) , C o p in g  (V ), E f fe c ts  o n  B & P  (V I)
C) Cognitive disturbances
OK - I’d now like to ask you some questions about your thinking and your decision making 
abilities since you started to take skunk.
Cl Increased indecisiveness with regard to insignificant choices between 
equal alternatives
(d if fe re n t to  loss o f  sp o n tan e ity  a n d  c a re free  respond ing  - B3)
• Is it more difficult to make decisions since you started smoking skunk, even about the 
most unimportant things, such as which washing powder to go for?
Rating: Frequency II
If needed: Subjective burden (IV), Effects on behaviour (VI), Areas of life
(VIII)
C2 Thought interference
(w hen  random th o u g h ts , u n re la te d  to  c u rre n t tho u g h ts  o r  ex te rn a l events d is tu rb  
th e  p e rso n 's  t r a in  o f  th o u g h t) ; N O T  obsessive persev era tio n  o f  th o u g h t (C .1.2), 
th o u g h t b lock ing  (C 3), o r  d is tra c tio n  o f  a tten tio n  by  ex te rn a l stim uli (B2)
• Since you started smoking skunk, do you sometimes find it difficult to take part in a
conversation or concentrate on a book or TV, because unimportant and unrelated
thoughts enter your mind?
• Do you sometimes have difficulties participating in a conversation, because your
thoughts drift away to other things that have nothing to do with what’s being discussed 
since you started smoking skunk?
Rating: Frequency II
If needed: Subjective burden (IV), Effects on performance (VI)
C3 Thought blockages
(5 su b ty p es: sudden  d isap p e a ra n ce  o f  old th o u g h t w ithou t rep lacem ent by new  one 
/  su d d e n  d isap p e a ra n ce  o f  old th o u g h t with rep lacem en t by new  one /  slow  and  
g ra d u a l d isap p e a ra n ce  o f  old th o u g h t w ith o u t new  though t a fte rw ard s  /  slow  and
g ra d u a l  d isap p e a ra n ce  o f  old th o u g h t, as new  in tru d e  a t  sam e tim e /  loss o f  th re a d , 
t r a in  o f  th o u g h ts
• Since you started smoking skunk, do you sometimes lose your train of thought, or do
your thoughts suddenly disappear as if they were cut short?
• Do your thoughts suddenly stop sometimes, as if they are being blocked or as if the
thought gradually fades?
• Does another thought take the place of the old one?
Rating: Frequency II
If needed: Subjective burden (IV), Coping with it by increasing effort (V),
Effects on performance (VI)
C4 Disturbance of receptive speech
(W h e n  re a d in g  o r  lis ten ing  to  o th e rs , th e  person  has difficulties o r  is unab le  to  
c o m p re h e n d  a n d  recognise  th e  m ean in g  o f  w ords, w o rd  sequences o r  sentences, e.g. 
in  co n v ersa tio n s , m ovies, T V  o r  rad io ) D O  N O T  score w hen due  to  co n cen tra tio n  
d ifficu lties  o r  w h en  o ccu ran ce  is on ly  d u rin g  v e ry  h igh dem and  task s  such  as a  
sc ien tific  lec tu re .
• Do you sometimes have difficulties understanding conversations, or when reading 
simple books or articles, since starting skunk?
• Since you started to take skunk, is it sometimes difficult to understand simple words or 
sentences -  is it like you are reading or hearing something in a foreign, but well-known 
language: so you recognise the word but have to think about its meaning?
Rating: Frequency II
If needed: Subjective burden (IV), Effects on performance, avoidance (VI)
C5 Disturbance of expressive speech
(p ro b lem s p ro d u c in g  a d e q u a te  w o rd s  -  w ord  fluency  an d  precision slowed dow n, 
d ifficu lty  find ing  c o rre c t w ords, som etim es w ords used w hich a re  associated  b u t 
n o t c o rre c t); N O T  a  d ifficu lty  expressing  feelings verbally  and  non-verbally .
• Do you speak as fluently and precisely as before you started smoking skunk? For 
example, is it sometimes difficult to find the right words or build the right sentences?
• Have you begun to use the same words and phrases again and again to avoid these
difficulties?
R a t in g :  F r e q u e n c y  I I
I f  n e e d e d :  S u b je c t iv e  b u r d e n  (IV ) , E f fe c ts  o n  p e r fo rm a n c e ,  s p e a k in g  (V I)
C 6  D i s t u r b a n c e  o f  i m m e d i a t e  r e c a l l
(complaints about not being able to remember things for even a very short time - 5 
to 40 sec)
• Do you sometimes have difficulties remembering things immediately since you started 
smoking skunk? For example, are the questions I’m asking hard to remember straight 
after I’ve asked them?
• Do you sometimes have difficulties to follow a conversation, because you quickly forget 
what was just said?
R a t in g :  F r e q u e n c y  I I
I f  n e e d e d :  S u b je c tiv e  b u r d e n  ( IV ) , C o p in g  (V ) , E ffe c ts  o n  p e r fo rm a n c e  (V I)
D) Disturbances in experiencing self and surrounding
I’m now going to ask you some questions now about your emotions and your beliefs about 
yourself.
D1 Decreased capacity to discriminate between different kinds of 
emotions
(a ll feelings o ften  experienced  as m onotone o r  ta in te d  w ith  a  dyspho ric  quality , 
even  , positive’ ones). N O T  c h an g e  in  m ood an d  em otiona l responsiveness (A2) o r  a 
d e c rea se  o f  positive  feeling to w a rd  o th e rs / p reviously  en joyed  activ ities (A3)
• Are you always able to tell the difference between unpleasant and pleasant, negative and 
positive feelings clearly and easily? How does this compare to before you started 
smoking skunk?
• Have all emotions become somehow unpleasant since you started skunk?
Rating: Frequency II
If needed: Subjective burden (IV)
D2 Increased emotional reactivity in response to routine social
interactions that affect the patient or his/her significant others 
(em phasis  on  socia l in te ra c tio n  n o t everyday  events like sad  m usic, T V  o r  books 
B U T  on em o tio n a l reac tiv ity  to  se lf a n d  sign ifican t o th e rs  w hich  m ay  have no t been 
so s tro n g  p rev io u sly  A N D  th e  p a r tic ip a n t is a w are  they  a re  over-reacting ); N O T  as 
th e  re su lt o f  a  specific tr ig g e r  like th o u g h t p e rsev era tio n  (O l)
• Do the actions or comments of others, or discussions and arguments, get you more 
worked up now than before you started smoking skunk?
• Do you have the feeling that you are more sensitive now -  that almost everything gets 
under your skin?
Rating: Frequency I
If needed: Subjective burden (IV), Effects on B&P (VI)
D3 Thought pressure
(g re a t  n u m b e r  o f  ra n d o m , d iffe ren t th o u g h ts / im ages e n te r  th e  m ind  a n d  d isap p e a r 
a g a in  in  q u ic k  sequences w ith o u t th e  person  being  ab le  to  su p p ress  o r  gu ide them ) 
N O T  th o u g h t in te rfe re n c e  (C l) , n o r  th ough  persevera tion  w h ere  m any  th o u g h ts / 
im ages com e fro m  sh a re d  th em e (O l)
• Do you sometimes have the feeling that you are not able to control your thoughts, in 
comparison to the time before you started smoking skunk - Do your thoughts just run 
wild, impossible to control?
• Do you sometimes jump from one subject to another so much that your single thoughts 
feel unrelated to each other, since you started smoking skunk?
Rating: Frequency II
If needed: Subjective burden (IV), Effects on B&P (VI)
D4 Unstable ideas of reference, vsubject-centrismf
(in d iv id u a l feels th e y  a re  th e  focus o f  a tten tio n  b u t has no c lea r reason  fo r  th is  a n d  
overcom es th is  q u ick ly  N O T  ideas o f  re fe rence  re la ted  to  depressive, social anx iety  
o r  p a ra n o id  beliefs)
• Do you sometimes feel that things going on around you have a special meaning for you, 
even though you know at the same time that this is improbable or impossible? How 
does this compare to before you started smoking skunk?
• Do you sometimes feel as if random things were meant especially for you, e.g. 
comments on the radio or TV? What does it take for you to realise that this is just a 
sudden idea and not true? How long does this idea last?
Rating: Frequency II
If needed: Severity (III), Subjective burden (IV), Areas of life (VIII)
D5 Changed perception of the face or body of others
(face  o r  body  o f  o th e rs  is seen as s tra n g e  an d  peculiar, e.g. co lour o f skin , eyes o r  
h a i r  - m ay lead  to  im p a ired  ab ility  to  recognise facial expressions)
• Do the faces or bodies of other people sometimes appear different or distorted since 
you started smoking skunk?
Rating: Frequency II
If needed: Severity (III), Subjective burden (IV), Effects on B&P (VI)
E) Body perception disturbances
General question:
Have you ever had unusual or peculiar body sensations, unlike those you normally experience or 
are familiar with? Can you describe them? Have you seen a doctor about it, and if so, what did 
they say?
IF  Y E S : E l
IF  N O  : G o  to  F
E l Unusual bodily sensations of numbness and stiffness
(resem b le  p a raes th esia s  incl. num bness  a n d  stiffness, w an d erin g  sensations o f 
stiffness, w hich  can  be  tra n s ie n t o r  ch ron ic . N O T  rea l m o to r blockages (0 1 0 ; 
w h e re  p e rson  can  n o t m ove), N O R  slow ing dow n o f  m ovem ents U N LE SS slow ing 
do w n  is accom pan ied  by sensa tions o f  stiffness, N O R  the  feeling th a t  th e  body, o r  
p a r ts  o f  it  do  n o t belong to  onese lf (F6)
• Have you sometimes experienced unusual, numb or stiff feelings in your arms or legs or 
in another part of your body, since you started smoking skunk?
• When you experience this stiffness / numbness, do you feel as if you are paralysed and 
cant move, or are you actually moving slower? (qu to rule out 010 etc)
Rating: F req uency II
If needed: Severity (III), Subjective Burden (IV), Effects on performance (VI),
Consulting a doctor (VII)
£2 Unusual bodily sensations of pain in a distinct area
(p a in fu l, o ften  long-lasting  sensa tions w ith  a  p iercing , tea rin g  o r  shoo ting  qua lity , 
w h ich  c a n t be neuro log ically  exp lained . O ften  o ccu r a t  ce rta in  tim es o f  day , like 
su d d e n  a tta c k ; often  acco m p an ied  by  affective d is tu rbances; d ep th  location  is also 
o fte n  d if f ic u l t  N O T  In ten se  feelings o f  being  e lectrified  (E4)
• Do you sometimes have a peculiar pain, like a piercing, tearing or shooting feeling, 
since you started smoking skunk? Where is it located; how deep is it?
• Is this pain different from pains you had before you started smoking skunk?
Rating: Frequency II
If needed: Severity (III), Subjective Burden (IV), Effects on performance (VI),
Consulting a doctor (VII)
£3 Migrating bodily sensations wandering through the body (fluctua ting ,
w a n d e rin g  sen sa tio n s a ro u n d  body , w hich  can  increase  to  som etim es pa in fu l / 
a tta ck - lik e  severity ); N O T  a  m o re  s ta tic  sensation  (E5)
• Do you sometimes have irritating and uncomfortable body sensations that move through 
your body, and can even become painful since you started smoking skunk? If you do, 
what route do they take?
• Is this moving sensation different from sensations or pains you had before you started 
smoking skunk?
Rating: Frequency II
If needed: Severity (III), Subjective Burden (IV), Effects on performance (VI),
Consulting a doctor (VII)
£4  Electric bodily sensations, feelings of being electrified
(feeling  like be ing  given an  e lec tric  shock, w hich a re  no t re la ted  to  ex ternal 
in fluences. I f  desc rib ed  as pa in fu l, only  score h e re  N O T  £ 2 . I f  th e  e lec tric  
sensa tions w h irl, w a n d e r  o r  c irc le  a ro u n d  the  body, score a t  E3 too)
• Since starting to take skunk, do you sometimes experience a feeling that is like being 
given an electric shock?
Rating: Frequency II
If needed: Severity (III), Quality of being new/different (IV), Subjective burden,
(VI), Effects on performance (VI), Consulting a doctor, (VII)
E5 Bodily sensations of movement, pulling or pressure inside the body or 
on its surface
(sensa tions  perceived  as i f  som eth ing  is ac tua lly  m oving inside th e  body, o rg an s  o r  
on  th e  sk in  - itch ing , v ib ra tin g , shak ing , knocking, trem b ling , qu ivering , tw itch ing , 
c raw ling , d igg ing , te a r in g , s tro k in g ); N O T  ju s t  a  sensations sw irling , c irc ling  
a ro u n d  body  (E 3)
• Since you started smoking skunk, do you sometimes have the feeling as if 
something is moving inside your body, or on your skin?
• How would you describe this feeling? Is it like a twitching, jumping, vibrating, 
knocking or trembling?
Rating: Frequency II
If needed: Severity (III), Subjective Burden (IV), Effects on performance (VI),
Consulting a doctor (VII)
E6 Sensations of the body or parts of it extending, diminishing, shrinking, 
enlarging, growing or constricting
(can  affec t w hole b ody  o r  ju s t  p a rts , a n d  generally  ‘a ttack -lik e ’. O ften  
acco m p an ied  by  affec tive  changes, w hich can  escalate  to  pan ic  depend ing  on the  
‘re a lity ’ o f th e  sensa tions); N O T  sensations o f  body being heavy, ligh t o r  em pty , 
fa lling  o r  s ink ing , N O R  depersona lisa tion .
• Do you sometimes feel as if your whole body or parts of it is going to shrink or
grow or change in some way?
Rating: Frequency II
If needed: Severity (III), Subjective Burden (IV), Effects on performance (VI),
Consulting a doctor (VII)
F) Perception disturbances
I’m going to ask you a few more questions about your vision and hearing now.
FI Hypersensitivity to light or certain optic stimuli
(N O T  sco red  i f  these  experiences o c cu r as a  re su lt o f  a  m ig raine , ep ilep tic  a u ra  o r  
a n o th e r  know n physical illness)
• Have you become much more sensitive to sunlight, or felt things were brighter than 
usual, since you started smoking skunk?
• Have you consulted a doctor about this? If so, what did they say?
Rating: Frequency II
I f  n e e d e d :  S u b je c t iv e  b u r d e n  ( IV ) , C o p in g  (V ), E f fe c ts  o n  B & P  (V I)
F2 Photopsia
(a re  s im ple  m oving  o r  fixed w h ite , b r ig h t o r  co loured  hallucinations in fo rm  o f
flashes, s ta r s , flam es, c irc les o r  v e ry  s tro n g , b lind ing  l ig h t  O N LY  S C O R E  w hen  it 
causes S U B JE C T IV E  co m p la in ts  a n d  is N O T  re la ted  by  th e  ind iv idual to  the  
o u ts id e  w o rld  b u t to  them selves)
• Do you sometimes see flashes of light or other very bright figures like stars, dots or flames 
in your eyes? Have you always had this, or has it developed since you started smoking 
skunk?
• Have you consulted a doctor about this? If so, what did they say?
R a t in g :  F r e q u e n c y  I I
I f  n e e d e d :  S u b je c t iv e  b u r d e n  (TV), E f fe c ts  o n  B & P  (V I)
F3 Micropsia, Macropsia
• Do objects ever appear bigger or smaller than they really are, or distorted in any way?
• Have you always had this, or has this developed since you started smoking skunk? 
R a t in g :  F r e q u e n c y  I I
I f  n e e d e d :  S e v e r ity  ( I I I ) ,  S u b je c t iv e  b u r d e n  (IV ), E ffe c ts  o n  B & P  (V I)
F4 Hypersensitivity to sounds or noise
(so u n d s  o f  u n ch an g ed  in tensity  o r  q u a lity  a re  experienced  as too  loud, d is trac tin g  
o r  annoy ing ; N O T  changed  in tensity , q u a lity  o f  sound , F5)
• Are you much more sensitive to sounds and noise in comparison to before you started 
smoking skunk?
• Have you consulted a doctor about this? If so, what did they say?
Rating: Frequency II
If needed: Subjective burden (IV), Effects on B&P (VI)
F5 Changes in the perceived intensity or quality of acoustic stimuli
(D o n o t sco re  a  sole hypersensitiv ity  to  sounds w ith o u t an y  qua lita tive  changes in  
a u d ito ry  p e rcep tio n s  (F4) o r  d e rea lisa tio n  -  w hich  also req u ires  v isual p e rcep tu a l 
d is to rtio n s  (0 8 )  here)
• Do you sometimes have strange problems with hearing? Can you describe them?
• Do you sometimes have sudden and short-lived difficulties with your hearing such as
sounds seeming muffled or less loud or short periods of deafness?
• Have you always had these experiences, or have they developed since you started smoking 
skunk?
• Have you consulted a doctor about this? If so, what did they say?
Rating: Frequency II
If needed: Severity (III), Subjective burden (IV), Effects on B&P (VI)
F6 Somatopsychic bodily depersonalisation
T h e  body o r  p a rts  o f  it a re  perceived  as no t belonging to  oneself anym ore , as 
isolated o r  sep ara ted  from  each  o th e r  o r  n o t existing a t  all O R  body is perceived  as 
falling  a p a r t/  body p a rts  seem  no longer to  be  connected , a lthough  a ll p a r ts  still 
belong to  the  person affected. (N O T  depersona lisation  n o r  v isual percep tions o f  
changes in  the  person’s face o r  expression  w hich  cause the  ind iv idual to  rep ea ted ly  
check  them selves in th e  m ir ro r)
• Do you sometimes feel as if parts of your body have been separated from the rest of 
your body or do not exist anymore?
• Are you sometimes unable to feel your body or parts of it?
• Do you sometimes have a feeling as if your body could fall apart like a jigsaw?
• Have you always had this, or is it an experience that has developed since starting to take 
skunk?
R a t in g :  F r e q u e n c y  I I
I f  n e e d e d :  S e v e r ity  ( I I I ) ,  S u b je c t iv e  b u rd e n  (IV ), E ffe c ts  o n  B & P  (V I) ,
C o n s u lt in g  a  d o c to r  (V II )
O) Optional Extras:
0 1  Thought perseveration
(usually re: events, conversations, mundane things that have happened a few hours 
earlier, maybe even the day before; thoughts all following the same theme. NOT a 
depressive rumination about a negative future, NOR thought interference (C2) where 
unimportant thought/image interferes with functioning without being constantly 
repeated, NOR thought pressure (D3) where there is a succession of unrelated 
thoughts)
• Do you sometimes have to think about past unimportant conversations or events, when 
you want to think about something else?
• Does this ever take the form of images in your mind’s eye?
R a t in g :  F re q u e n c y  I I
I f  n e e d e d : S u b je c tiv e  B u r d e n  ( IV ) , C o p in g  (V ), E ffe c ts  o n  B & P  (V I)
0 2  Decreased ability to discriminate between ideas and perception, pure 
fantasy and true memories
• Are you sometimes unsure whether you actually see or hear something, or if you just 
imagined it?
• Do you sometimes become confused whether you have actually done certain things in 
the past or just imagined them? Do you ever ask others to make sure?
• Have you always had these experiences, or have they developed since you started 
smoking skunk?
R a t in g :  F re q u e n c y  I I
I f  n e e d e d :  S u b je c tiv e  B u rd e n  (IV ), C o p in g  (V ), E ffe c ts  o n  B & P  (V I)
0 7  Captivation of attention by details of the visual field
(N O T  ‘feeling  overly  d is tra c ted  by  stim u li’ (B2) w here  a tten tio n  is easily d is trac ted  
by  all k ind  o f  th in g s  going  on  in th e  env ironm en t, so th a t  s/he h as  difficulties to  
focus on  one th ing , here , th e  a tten tion  is fixed on one th in g  an d  th e  re s t o f  the 
e n v iro n m e n t is n o t p a id  any  a tten tio n  anym ore)
• Since you starting smoking skunk, have you ever noticed that specific aspects of the 
environment you are looking at really stand out in a striking way, and seem somehow 
isolated from the rest?
• Do you ever have to stare at these details, without actually wanting to?
Rating: Frequency II
If needed: Subjective Burden (IV), Coping (V), Effects on performance,
behaviour, avoidance (VI)
08  Derealisation
• Since starting to take skunk, do you sometimes experience your surroundings as
changed, unreal or strange? As if the world around you isn’t quite real? (subtype 1)
• Have there been times when you have experienced a high, euphoric mood during which 
your surroundings, the landscape, animals or people seemed different, somehow great, 
impressive and moving? (subtype 2)
Rating: Frequency II
If needed: Severity (III), Subjective Burden (IV)
010 Motor Blockages
(Im pedim ent o r  com plete  b lockage o f  in tended  m o to r actions th a t a p p e a r  a tta c k ­
like, all o f  a  sudden , an d  van ish  quickly)
• Are you sometimes, especially in the morning, suddenly unable to speak or move 
although you are fully awake?
R a t in g :  F r e q u e n c y  I I
I f  n e e d e d :  S u b je c t iv e  B u r d e n  (IV ), C o p in g  (V ), E f fe c ts  o n  B & P  (V I)
AND FINALLY....
A r e  th e r e  a n y  o th e r  c h a n g e s  to  h o w  y o u r  m in d  w o rk s  I  m a y  h a v e  m is se d ?  o r  a n y  
fe e lin g s  o r  b e h a v io u r s  t h a t  y o u  t h in k  h a v e  c h a n g e d  s in c e  y o u  s t a r t e d  s m o k in g  
s k u n k ?
H o w  o f te n  h a s  th is  a f fe c te d  y o u ?
H o w  m u c h  d o e s  i t  a f fe c t  y o u ?
F r e q u e n c y
Looking at this scale and smoking into account everything you have just told me, how frequently 
do you believe this.............. has occurred in the last week?
S e v e r i ty  ( I I I )
Taking into account everything you have told me how severe has this been?
S u b je c t iv e  B u r d e n  (IV )
Smoking into account eveiything you have just told me, how burdened do you feel by this? 
C o p in g  (V )
Smoking into account everything you have just told me, do you believe you are currently able to
cope with difficulties with this or do you think that the difficulties are not bad enough to
have to “cope” with them?
E f fe c ts  o n  B e h a v io u r  &  P e r f o r m a n c e  (V I)
Do you currently avoid certain places, situations, people or activities because of 
this.......................... ?
Include information the participant has told you previously about their behaviour and 
functioning to judge this answer.
E f fe c ts  o n  q u a l i ty  o f  life  (V I)
Smoking into account eveiything you have just told me, how has x affected your quality
of life?
C o n s u lta t io n  w ith  a  d o c to r  (V II)
Have you considered consulting a doctor about these experiences? If so, how many
appointments have you had, and how many doctors have you seen?
A r e a s  o f  life (V II I )
Smoking into account everything you have just told me, how many areas of your life do you
believe x has affected in the last week?
